<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CADUET - amlodipine besylate and atorvastatin calcium tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CADUET® (amlodipine besylate and atorvastatin calcium) tablets 
combine the calcium channel blocker amlodipine besylate with the lipid-lowering 
agent atorvastatin calcium.</p>
<p>The amlodipine besylate component of CADUET is chemically described as 
3-ethyl-5-methyl 
(±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, 
monobenzenesulphonate. Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">5</span>•C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S.</p>
<p>The atorvastatin calcium component of CADUET is chemically described as 
[R-(R*, R*)]-2-(4-fluorophenyl)-β, 
δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic 
acid, calcium salt (2:1) trihydrate. Its empirical formula is (C<span class="Sub">33</span>H<span class="Sub">34</span>FN<span class="Sub">2</span>O<span class="Sub">5</span>)<span class="Sub">2</span>Ca•3H<span class="Sub">2</span>O.</p>The structural formulae for amlodipine besylate and atorvastatin calcium are 
shown below.<div class="Figure"><img alt="image of both chemical structures" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=chemical%20structures.jpg"></div>
<p>CADUET contains amlodipine besylate, a white to off-white crystalline powder, 
and atorvastatin calcium, also a white to off-white crystalline powder. 
Amlodipine besylate has a molecular weight of 567.1 and atorvastatin calcium has 
a molecular weight of 1209.42. Amlodipine besylate is slightly soluble in water 
and sparingly soluble in ethanol. Atorvastatin calcium is insoluble in aqueous 
solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in 
distilled water, pH 7.4 phosphate buffer, and acetonitrile; slightly soluble in 
ethanol, and freely soluble in methanol.</p>
<p>CADUET tablets are formulated for oral administration in the following 
strength combinations:</p>
<a name="i101e32c7-ceb3-4328-8b01-25edbf093bdd"></a><table width="100%">
<caption><span>Table 1. CADUET Tablet Strengths</span></caption>
<col align="left" width="12%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<col align="left" width="8%">
<thead><tr class="First Last">
<th align="left"><br></th>
<th align="left">2.5 mg/<br>10mg</th>
<th align="left">2.5 mg/<br>20mg</th>
<th align="left">2.5 mg/<br>40mg</th>
<th align="left">5 mg/10<br>mg</th>
<th align="left">5 mg/20<br>mg</th>
<th align="left">5 mg/40<br>mg</th>
<th align="left">5 mg/80<br>mg</th>
<th align="left">10 mg/<br>10 mg</th>
<th align="left">10 mg/<br>20 mg</th>
<th align="left">10 mg/<br>40 mg</th>
<th align="left">10 mg/<br>80 mg</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">amlodipine<br>equivalent<br>(mg)</td>
<td align="left">2.5</td>
<td align="left">2.5</td>
<td align="left">2.5</td>
<td align="left">5</td>
<td align="left">5</td>
<td align="left">5</td>
<td align="left">5</td>
<td align="left">10</td>
<td align="left">10</td>
<td align="left">10</td>
<td align="left">10</td>
</tr>
<tr class="Last">
<td align="left">atorvastatin<br>equivalent<br>(mg)</td>
<td align="left">10</td>
<td align="left">20</td>
<td align="left">40</td>
<td align="left">10</td>
<td align="left">20</td>
<td align="left">40</td>
<td align="left">80</td>
<td align="left">10</td>
<td align="left">20</td>
<td align="left">40</td>
<td align="left">80</td>
</tr>
</tbody>
</table>
<p>Each tablet also contains calcium carbonate, croscarmellose sodium, 
microcrystalline cellulose, pregelatinized starch, polysorbate 80, hydroxypropyl 
cellulose, purified water, colloidal silicon dioxide (anhydrous), magnesium 
stearate, Opadry® II White 85F28751 (polyvinyl alcohol, titanium dioxide, PEG 
3000 and talc) or Opadry® II Blue 85F10919 (polyvinyl alcohol, titanium dioxide, 
PEG 3000, talc and FD&amp;C blue #2). Combinations of atorvastatin with 2.5 mg 
and 5 mg amlodipine are film coated white, and combinations of atorvastatin with 
10 mg amlodipine are film coated blue.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a>Mechanism of Action<a href="http://"></a><a href="http://"></a>CADUET<p class="First">CADUET is a combination of two drugs, a dihydropyridine calcium 
channel blocker amlodipine and an HMG-CoA reductase inhibitor atorvastatin. The 
amlodipine component of CADUET inhibits the transmembrane influx of calcium ions 
into vascular smooth muscle and cardiac muscle. The atorvastatin component of 
CADUET is a selective, competitive inhibitor of HMG-CoA reductase (statin), the 
rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to 
mevalonate, a precursor of sterols, including <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<a href="http://"></a><a href="http://"></a>Amlodipine<p>Experimental data suggest that amlodipine binds to both 
dihydropyridine and nondihydropyridine binding sites. The contractile processes 
of cardiac muscle and vascular smooth muscle are dependent upon the movement of 
extracellular calcium ions into these cells through specific ion channels. 
Amlodipine inhibits calcium ion influx across cell membranes selectively, with a 
greater effect on vascular smooth muscle cells than on cardiac muscle cells. 
Negative inotropic effects can be detected <span class="Italics">in vitro</span> 
but such effects have not been seen in intact animals at therapeutic doses. 
Serum calcium concentration is not affected by amlodipine.</p>
<p>Amlodipine is a peripheral arterial vasodilator that acts directly on 
vascular smooth muscle to cause a reduction in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> 
and reduction in blood pressure.</p>
<p>The precise mechanisms by which amlodipine relieves angina have not been 
fully delineated, but are thought to include the following:</p>
<p>Exertional Angina: In patients with exertional angina, amlodipine reduces the 
total peripheral resistance (afterload) against which the heart works and 
reduces the rate pressure product, and thus myocardial oxygen demand, at any 
given level of exercise.</p>
<p>Vasospastic Angina: Amlodipine has been demonstrated to block constriction 
and restore blood flow in coronary arteries and arterioles in response to 
calcium, potassium epinephrine, serotonin, and thromboxane A<span class="Sub">2</span> analog in experimental animal models and in human coronary 
vessels <span class="Italics">in vitro</span>. This inhibition of coronary spasm 
is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's 
or variant) angina.</p>
<a href="http://"></a><a href="http://"></a>Atorvastatin<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and triglycerides circulate in the bloodstream as 
part of lipoprotein complexes. With ultracentrifugation, these complexes 
separate into HDL (high-density lipoprotein), IDL (intermediate-density 
lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density 
lipoprotein) fractions. Triglycerides (TG) and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in the liver are 
incorporated into VLDL and released into the plasma for delivery to peripheral 
tissues. LDL is formed from VLDL and is catabolized primarily through the 
high-affinity LDL receptor.</p>
<p>Clinical and pathologic studies show that elevated plasma levels of total 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (total-C), LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>) 
promote human <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> and are risk factors for developing cardiovascular 
disease, while increased levels of HDL-C are associated with a decreased 
cardiovascular risk.</p>
<p>Epidemiologic investigations have established that cardiovascular morbidity 
and mortality vary directly with the level of total-C and LDL-C, and inversely 
with the level of HDL-C.</p>
<p>In animal models, atorvastatin lowers plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and lipoprotein 
levels by inhibiting HMG-CoA reductase and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis in the liver 
and by increasing the number of hepatic LDL receptors on the cell-surface to 
enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production 
and the number of LDL particles.</p>
<p>Atorvastatin reduces total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> in patients with homozygous 
and <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (FH), nonfamilial forms of 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Atorvastatin also reduces VLDL-C 
and TG and produces variable increases in HDL-C and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> A-1. 
Atorvastatin reduces total-C, LDL-C, VLDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, TG, and non-HDL-C, and 
increases HDL-C in patients with isolated <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. Atorvastatin 
reduces intermediate density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (IDL-C) in patients with 
dysbetalipoproteinemia.</p>
<p>Like LDL, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-enriched triglyceride-rich lipoproteins, including 
VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote 
<span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Elevated plasma triglycerides are frequently found in a triad 
with low HDL-C levels and small LDL particles, as well as in association with 
non-lipid metabolic risk factors for coronary heart disease. As such, total 
plasma TG has not consistently been shown to be an independent risk factor for 
CHD. Furthermore, the independent effect of raising HDL or lowering TG on the 
risk of coronary and cardiovascular morbidity and mortality has not been 
determined.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pharmacokinetics and Metabolism<a href="http://"></a><a href="http://"></a>Absorption<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>After oral administration of therapeutic doses of amlodipine 
alone, absorption produces peak plasma concentrations between 6 and 12 hours. 
Absolute bioavailability has been estimated to be between 64% and 90%.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>After oral administration alone, atorvastatin is rapidly 
absorbed; maximum plasma concentrations occur within 1 to 2 hours. Extent of 
absorption increases in proportion to atorvastatin dose. The absolute 
bioavailability of atorvastatin (parent drug) is approximately 14% and the 
systemic availability of HMG-CoA reductase inhibitory activity is approximately 
30%. The low systemic availability is attributed to presystemic clearance in 
gastrointestinal mucosa and/or hepatic first-pass metabolism. Plasma 
atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) 
following evening drug administration compared with morning. However, LDL-C 
reduction is the same regardless of the time of day of drug administration (see 
<span class="Bold"><a href="#dosage_administration">DOSAGE AND 
ADMINISTRATION</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Studies with CADUET<p>Following oral administration of CADUET peak plasma 
concentrations of amlodipine and atorvastatin are seen at 6 to 12 hours and 1 to 
2 hours post dosing, respectively. The rate and extent of absorption 
(bioavailability) of amlodipine and atorvastatin from CADUET are not 
significantly different from the bioavailability of amlodipine and atorvastatin 
administered separately (see above).</p>
<p>The bioavailability of amlodipine from CADUET was not affected by food. Food 
decreases the rate and extent of absorption of atorvastatin from CADUET by 
approximately 32% and 11%, respectively, as it does with atorvastatin when given 
alone. LDL-C reduction is similar whether atorvastatin is given with or without 
food.</p>
<a href="http://"></a><a href="http://"></a>Distribution<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p><span class="Italics">Ex vivo</span> studies have shown that 
approximately 93% of the circulating amlodipine drug is bound to plasma proteins 
in hypertensive patients. Steady-state plasma levels of amlodipine are reached 
after 7 to 8 days of consecutive daily dosing.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Mean volume of distribution of atorvastatin is approximately 381 
liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of 
approximately 0.25 indicates poor drug penetration into red blood cells. Based 
on observations in rats, atorvastatin calcium is likely to be secreted in human 
milk (see <span class="Bold"><a href="#contraindications_pregnancy">CONTRAINDICATIONS, Pregnancy and 
Lactation</a>,</span> and <span class="Bold"><a href="#precautions_nursing">PRECAUTIONS, Nursing Mothers</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Metabolism<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>Amlodipine is extensively (about 90%) converted to inactive 
metabolites via hepatic metabolism.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Atorvastatin is extensively metabolized to ortho- and 
parahydroxylated derivatives and various beta-oxidation products. <span class="Italics">In vitro</span> inhibition of HMG-CoA reductase by ortho- and 
parahydroxylated metabolites is equivalent to that of atorvastatin. 
Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is 
attributed to active metabolites. <span class="Italics">In vitro</span> studies 
suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, 
consistent with increased plasma concentrations of atorvastatin in humans 
following coadministration with erythromycin, a known inhibitor of this isozyme 
(see <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug 
Interactions</a></span>). In animals, the ortho-hydroxy metabolite undergoes 
further glucuronidation.</p>
<a href="http://"></a><a href="http://"></a>Excretion<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>Elimination from the plasma is biphasic with a terminal 
elimination half-life of about 30–50 hours. Ten percent of the parent amlodipine 
compound and 60% of the metabolites of amlodipine are excreted in the 
urine.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Atorvastatin and its metabolites are eliminated primarily in bile 
following hepatic and/or extra-hepatic metabolism; however, the drug does not 
appear to undergo enterohepatic recirculation. Mean plasma elimination half-life 
of atorvastatin in humans is approximately 14 hours, but the half-life of 
inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the 
contribution of active metabolites. Less than 2% of a dose of atorvastatin is 
recovered in urine following oral administration.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Specific Populations<a href="http://"></a><a href="http://"></a>Geriatric<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>Elderly patients have decreased clearance of amlodipine with a 
resulting increase in AUC of approximately 40–60%, and a lower initial dose of 
amlodipine may be required.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Plasma concentrations of atorvastatin are higher (approximately 
40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than 
in young adults. Clinical data suggest a greater degree of LDL-lowering at any 
dose of atorvastatin in the elderly population compared to younger adults (see 
<span class="Bold"><a href="#precautions_geriatric">PRECAUTIONS</a></span>, <span class="Bold"><a href="#precautions_geriatric">Geriatric Use</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Pediatric<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>Sixty-two hypertensive patients aged 6 to 17 years received doses 
of amlodipine between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of 
distribution were similar to values in adults.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Pharmacokinetic data in the pediatric population are not 
available.</p>
<a href="http://"></a><a href="http://"></a>Gender<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Plasma concentrations of atorvastatin in women differ from those 
in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there 
is no clinically significant difference in LDL-C reduction with atorvastatin 
between men and women.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>The pharmacokinetics of amlodipine are not significantly 
influenced by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> may therefore 
receive the usual initial amlodipine dose.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span> has no influence on the plasma concentrations or 
LDL-C reduction of atorvastatin; thus, dose adjustment of atorvastatin in 
patients with renal dysfunction is not necessary (see <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal 
Muscle</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Hemodialysis<p>While studies have not been conducted in patients with end-stage 
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, hemodialysis is not expected to clear atorvastatin or amlodipine 
since both drugs are extensively bound to plasma proteins.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><p>Atorvastatin is contraindicated in patients with active liver 
disease.</p>
<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>Elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have 
decreased clearance of amlodipine with a resulting increase in AUC of 
approximately 40–60%.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>In patients with chronic <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span>, plasma 
concentrations of atorvastatin are markedly increased. Cmax and AUC are each 
4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC of 
atorvastatin are approximately 16-fold and 11-fold increased, respectively, in 
patients with Childs-Pugh B disease (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>).</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span><a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>In patients with moderate to severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the increase 
in AUC for amlodipine was similar to that seen in the elderly and in patients 
with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
<a href="http://"></a><a href="http://"></a>Pharmacokinetic Studies of Atorvastatin and 
Co-Administered Drugs<a name="i44bf79ec-29df-484f-846e-c6f9dc2813b1"></a><table width="100%">
<caption><span>TABLE 2. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Co-administered drug and dosing regimen</span><br>
</td>
<td><br></td>
<td>
<span class="Bold">Atorvastatin</span><br>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>
<span class="Bold">Dose (mg)</span><br>
</td>
<td>
<span class="Bold">Change in AUC</span><a href="#footnote-1">*</a>
</td>
<td>
<span class="Bold">Change in Cmax</span><a href="#footnote-1">*</a>
</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Cyclosporine 5.2 
mg/kg/day, stable dose</td>
<td>10 mg QD for 28 days<br>
</td>
<td>↑ 8.7-fold</td>
<td>↑ 10.7-fold</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Lopinavir 400 mg BID/ ritonavir 100 mg BID, 
14 days</td>
<td>20 mg QD for 4 days<br>
</td>
<td>↑ 5.9-fold</td>
<td>↑ 4.7-fold</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Ritonavir 400 mg BID/ saquinavir 400mg BID, 
15 days</td>
<td>40 mg QD for 4 days<br>
</td>
<td>↑ 3.9-fold</td>
<td>↑ 4.3-fold</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Clarithromycin 500 mg BID, 9 days </td>
<td>80 mg QD for 8 days<br>
</td>
<td>↑ 4.4-fold</td>
<td>↑ 5.4-fold</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Itraconazole 200 mg QD, 4 days </td>
<td>40 mg SD<br>
</td>
<td>↑ 3.3-fold</td>
<td>↑ 20%<br>
</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Grapefruit Juice, 240 mL QD <a href="#footnote-3">‡</a>
</td>
<td>40 mg, SD<br>
</td>
<td>↑ 37%<br>
</td>
<td>↑ 16%</td>
</tr>
<tr>
<td>Diltiazem 240 mg QD, 28 days<br>
</td>
<td>40 mg, SD<br>
</td>
<td>↑ 51%</td>
<td>No change<br>
</td>
</tr>
<tr>
<td>Erythromycin 500 mg QID, 7 days<br>
</td>
<td>10 mg, SD<br>
</td>
<td>↑ 33%</td>
<td>↑ 38%</td>
</tr>
<tr>
<td>Amlodipine 10 mg, single dose<br>
</td>
<td>80 mg, SD<br>
</td>
<td>↑ 15%</td>
<td>↓ 12%</td>
</tr>
<tr>
<td>Cimetidine 300 mg QD, 4 weeks<br>
</td>
<td>10 mg QD for 2 weeks<br>
</td>
<td>↓ Less than 1%</td>
<td>↓ 11%</td>
</tr>
<tr>
<td>Colestipol 10 mg BID, 28 weeks<br>
</td>
<td>40 mg QD for 28 weeks<br>
</td>
<td>Not determined<br>
</td>
<td>↓ 26%<a href="#footnote-4">§</a>
</td>
</tr>
<tr>
<td>Maalox TC® 30 mL QD, 17 days </td>
<td>10 mg QD for 15 days<br>
</td>
<td>↓ 33%</td>
<td>↓ 34%</td>
</tr>
<tr>
<td>Efavirenz 600 mg QD, 14 days<br>
</td>
<td>10 mg for 3 days<br>
</td>
<td>↓ 41%</td>
<td>↓ 1%</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Rifampin 600 mg QD, 7 days 
(co-administered) <a href="#footnote-5">¶</a>
</td>
<td>40 mg SD<br>
</td>
<td>↑ 30%</td>
<td>↑ 2.7-fold</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Rifampin 600 mg QD, 5 days 
(doses separated) <a href="#footnote-5">¶</a>
</td>
<td>40 mg SD<br>
</td>
<td>↓ 80%</td>
<td>↓ 40%</td>
</tr>
<tr>
<td>
<a href="#footnote-2">†</a>Gemfibrozil 600mg BID, 7 days </td>
<td>40 mg SD<br>
</td>
<td>↑ 35%</td>
<td>↓ Less than 1%</td>
</tr>
<tr class="Last">
<td>
<a href="#footnote-2">†</a>Fenofibrate 160mg QD, 7 days</td>
<td>40 mg SD<br>
</td>
<td>↑ 3%</td>
<td>↑ 2%</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-1">*</a>     Data given as x-fold change represent a simple ratio between co-administration 
and atorvastatin alone (i.e., 1-fold = no change). Data given as % change 
represent % difference relative to atorvastatin alone (i.e., 0% = no change). <br><a href="http://SPLForm_DrugListing.xhtml#footnote-2">†</a>     See <a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a> and <a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a> for 
clinical significance.<br><a href="http://SPLForm_DrugListing.xhtml#footnote-3">‡</a>     Greater increases in AUC (up to 2.5-fold) and/or Cmax (up to 71%) have been reported 
with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day). <br><a href="http://SPLForm_DrugListing.xhtml#footnote-4">§</a>     Single sample taken 8-16 h post dose.<br><a href="http://SPLForm_DrugListing.xhtml#footnote-5">¶</a>     Due to the dual interaction mechanism of rifampin, simultaneous co-administration of 
atorvastatin with rifampin is recommended, as delayed administration of 
atorvastatin after administration of rifampin has been associated with a 
significant reduction in atorvastatin plasma concentrations.<br><br><br><br><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3"></a><p></p>
<a name="i5c767077-05cc-4504-8ae7-471852e578a0"></a><table width="100%">
<caption><span>TABLE 3. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Atorvastatin</span><br>
</td>
<td>
<span class="Bold">Co-administered</span><br>
</td>
<td>
<span class="Bold">drug and dosing regimen</span><br>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>
<span class="Bold">Drug/Dose (mg)</span><br>
</td>
<td>
<span class="Bold">Change in AUC</span><br>
</td>
<td>
<span class="Bold">Change in Cmax</span><br>
</td>
</tr>
<tr>
<td>80 mg QD for 15 days                    <br>
</td>
<td>Antipyrine, 600 mg SD<br>
</td>
<td>↑ 3%</td>
<td>↓ 11%</td>
</tr>
<tr>
<td>80 mg QD for 14 days<br>
</td>
<td>
<a href="#footnote-6">*</a> Digoxin 0.25 mg 
QD, 20 days</td>
<td>↑ 15%</td>
<td>↑ 20%</td>
</tr>
<tr>
<td>40 mg QD for 22 days                                           <br>
</td>
<td>Oral contraceptive QD, 2 months       <br>
</td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>- norethindrone 1 mg<br>
</td>
<td>↑ 28%</td>
<td>↑ 23%</td>
</tr>
<tr class="Last">
<td><br></td>
<td>- ethinyl estradiol 35µg</td>
<td>↑ 19%</td>
<td>↑ 30%</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-6">*</a>     See <a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a> 
for clinical significance.<br><br><br><br><a href="http://"></a>Pharmacodynamics<a href="http://"></a><a href="http://"></a>Hemodynamic Effects of Amlodipine<p class="First">Following administration of therapeutic doses to patients with 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, amlodipine produces vasodilation resulting in a reduction of 
supine and standing blood pressures. These decreases in blood pressure are not 
accompanied by a significant change in heart rate or plasma catecholamine levels 
with chronic dosing. Although the acute intravenous administration of amlodipine 
decreases arterial blood pressure and increases heart rate in hemodynamic 
studies of patients with chronic stable angina, chronic administration of oral 
amlodipine in clinical trials did not lead to clinically significant changes in 
heart rate or blood pressures in normotensive patients with angina.</p>
<p>With chronic once daily oral administration of amlodipine, antihypertensive 
effectiveness is maintained for at least 24 hours. Plasma concentrations 
correlate with effect in both young and elderly patients. The magnitude of 
reduction in blood pressure with amlodipine is also correlated with the height 
of pretreatment elevation; thus, individuals with moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> 
(diastolic pressure 105–114 mmHg) had about a 50% greater response than patients 
with mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 90–104 mmHg). Normotensive subjects 
experienced no clinically significant change in blood pressures (+1/–2 
mmHg).</p>
<p>In hypertensive patients with normal renal function, therapeutic doses of 
amlodipine resulted in a decrease in renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and an increase 
in glomerular filtration rate and effective renal plasma flow without change in 
filtration fraction or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>.</p>
<p>As with other calcium channel blockers, hemodynamic measurements of cardiac 
function at rest and during exercise (or pacing) in patients with normal 
ventricular function treated with amlodipine have generally demonstrated a small 
increase in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> without significant influence on dP/dt or on left 
ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine 
has not been associated with a negative inotropic effect when administered in 
the therapeutic dose range to intact animals and man, even when co-administered 
with beta-blockers to man. Similar findings, however, have been observed in 
normals or well-compensated patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with agents possessing 
significant negative inotropic effects.</p>
<a href="http://"></a><a href="http://"></a>Electrophysiologic Effects of Amlodipine<p>Amlodipine does not change sinoatrial nodal function or 
atrioventricular conduction in intact animals or man. In patients with chronic 
stable angina, intravenous administration of 10 mg did not significantly alter 
A-H and H-V conduction and sinus node recovery time after pacing. Similar 
results were obtained in patients receiving amlodipine and concomitant beta 
blockers. In clinical studies in which amlodipine was administered in 
combination with beta-blockers to patients with either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina, 
no adverse effects on electrocardiographic parameters were observed. In clinical 
trials with angina patients alone, amlodipine therapy did not alter 
electrocardiographic intervals or produce higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV blocks</span>.</p>
<a href="http://"></a><a href="http://"></a>LDL-C Reduction with Atorvastatin<p>Atorvastatin as well as some of its metabolites are 
pharmacologically active in humans. The liver is the primary site of action and 
the principal site of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and LDL clearance. Drug dosage, 
rather than systemic drug concentration, correlates better with LDL-C reduction. 
Individualization of drug dosage should be based on therapeutic response (see 
<span class="Bold"><a href="#dosage_administration">DOSAGE AND 
ADMINISTRATION</a></span>).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Clinical Studies<a href="http://"></a><a href="http://"></a><a href="http://"></a>Clinical Studies with Amlodipine<a href="http://"></a><a href="http://"></a>Amlodipine Effects in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span><a href="http://"></a><a href="http://"></a>Adult Patients<p>The antihypertensive efficacy of amlodipine has been demonstrated 
in a total of 15 double-blind, placebo-controlled, randomized studies involving 
800 patients on amlodipine and 538 on placebo. Once daily administration 
produced statistically significant placebo-corrected reductions in supine and 
standing blood pressures at 24 hours postdose, averaging about 12/6 mmHg in the 
standing position and 13/7 mmHg in the supine position in patients with mild to 
moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Maintenance of the blood pressure effect over the 24-hour 
dosing interval was observed, with little difference in peak and trough effect. 
Tolerance was not demonstrated in patients studied for up to 1 year. The 3 
parallel, fixed doses, dose response studies showed that the reduction in supine 
and standing blood pressures was dose-related within the recommended dosing 
range. Effects on diastolic pressure were similar in young and older patients. 
The effect on systolic pressure was greater in older patients, perhaps because 
of greater baseline systolic pressure. Effects were similar in black patients 
and in white patients.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Patients<p>Two-hundred sixty-eight hypertensive patients aged 6 to 17 years 
were randomized first to amlodipine 2.5 or 5 mg once daily for 4 weeks and then 
randomized again to the same dose or to placebo for another 4 weeks. Patients 
receiving 5 mg amlodipine at the end of 8 weeks had lower blood pressure than 
those secondarily randomized to placebo. The magnitude of the treatment effect 
is difficult to interpret, but it is probably less than 5 mmHg systolic on the 5 
mg dose. Adverse events were similar to those seen in adults.</p>
<a href="http://"></a><a href="http://"></a>Amlodipine Effects in Chronic Stable Angina<p>The effectiveness of 5–10 mg/day of amlodipine in 
exercise-induced angina has been evaluated in 8 placebo-controlled, double-blind 
clinical trials of up to 6 weeks duration involving 1038 patients (684 
amlodipine, 354 placebo) with chronic stable angina. In 5 of the 8 studies, 
significant increases in exercise time (bicycle or treadmill) were seen with the 
10 mg dose. Increases in symptom-limited exercise time averaged 12.8% (63 sec) 
for amlodipine 10 mg, and averaged 7.9% (38 sec) for amlodipine 5 mg. Amlodipine 
10 mg also increased time to 1 mm ST segment deviation in several studies and 
decreased <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina attack</span> rate. The sustained efficacy of amlodipine in angina 
patients has been demonstrated over long-term dosing. In patients with angina, 
there were no clinically significant reductions in blood pressures (4/1 mmHg) or 
changes in heart rate (+0.3 bpm).</p>
<a href="http://"></a><a href="http://"></a>Amlodipine Effects in Vasospastic Angina<p>In a double-blind, placebo-controlled clinical trial of 4 weeks 
duration in 50 patients, amlodipine therapy decreased attacks by approximately 
4/week compared with a placebo decrease of approximately 1/week (p less than 0.01). Two 
of 23 amlodipine and 7 of 27 placebo patients discontinued from the study due to 
lack of clinical improvement.</p>
<a href="http://"></a><a href="http://"></a>Amlodipine Effects in Documented Coronary Artery 
Disease<p>In PREVENT, 825 patients with angiographically documented 
<span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> were randomized to amlodipine (5–10 mg once daily) or 
placebo and followed for 3 years. Although the study did not show significance 
on the primary objective of change in coronary luminal diameter as assessed by 
quantitative coronary angiography, the data suggested a favorable outcome with 
respect to fewer hospitalizations for angina and revascularization procedures in 
patients with CAD.</p>
<p>CAMELOT enrolled 1318 patients with CAD recently documented by angiography, 
without left main <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span> and without <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or an ejection 
fraction less than 40%. Patients (76% males, 89% Caucasian, 93% enrolled at US sites, 
89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% 
with a stent) were randomized to double-blind treatment with either amlodipine 
(5 – 10 mg once daily) or placebo in addition to standard care that included 
aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), 
anti-coagulants (40%), and diuretics (32%), but excluded other calcium channel 
blockers. The mean duration of follow-up was 19 months. The primary endpoint was 
the time to first occurrence of one of the following events: hospitalization for 
<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, coronary revascularization, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, 
cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, hospitalization for heart 
failure, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/TIA, or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. A total of 110 (16.6%) and 
151 (23.1%) first events occurred in the amlodipine and placebo groups 
respectively for a hazard ratio of 0.691 (95% CI: 0.540–0.884, p= 0.003). The 
primary endpoint is summarized in Figure 1 below. The outcome of this study was 
largely derived from the prevention of hospitalizations for angina and the 
prevention of revascularization procedures (see <a href="#Table4">Table 4</a>). 
Effects in various subgroups are shown in Figure 2.</p>
<p>In a angiographic substudy (n=274) conducted within CAMELOT, there was no 
significant difference between amlodipine and placebo on the change of atheroma 
volume in the coronary artery as assessed by intravascular ultrasound.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4"></a><p></p>
<span class="Bold">Figure 1: Kaplan-Meier analysis of composite clinical outcomes 
for amlodipine</span><br><span class="Bold">versus placebo</span><br><div class="Figure"><img alt="image of Figure 1 graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Figure%201%20graph.jpg"></div>
<br><span class="Bold">Figure 2 – Effects on primary endpoint of amlodipine versus 
placebo across sub-groups</span><br><span class="Bold"></span><div class="Figure"><img alt="image of Figure 2 chart" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Figure%202%20Chart.jpg"></div>
<br><br>Table 4 below summarizes the significant composite endpoint and clinical 
outcomes from the composites of the primary endpoint. The other components of 
the primary endpoint including cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, resuscitated cardiac 
arrest, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/TIA, or 
<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> did not demonstrate a significant difference between 
amlodipine and placebo.<a name="i2ec315d5-35ed-4477-8762-28c71630174e"></a><table width="65%">
<caption><span>Table 4. Incidence of Significant Clinical Outcomes for CAMELOT </span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Clinical Outcomes<br>N (%)<br></span></td>
<td><span class="Bold">Amlodipine<br>(N=663)<br></span></td>
<td><span class="Bold">Placebo<br>(N=655)<br></span></td>
<td><span class="Bold">Risk Reduction<br>(p-value)<br></span></td>
</tr>
<tr>
<td>
<span class="Bold">Composite CV</span><br>
</td>
<td><span class="Bold">110</span></td>
<td><span class="Bold">151</span></td>
<td><span class="Bold">31%<br></span></td>
</tr>
<tr>
<td>
<span class="Bold">Endpoint</span><br>
</td>
<td>
<span class="Bold">(16.6)</span><br>
</td>
<td>
<span class="Bold">(23.1)</span><br>
</td>
<td><span class="Bold">(0.003)</span></td>
</tr>
<tr>
<td>Hospitalization for<br>
</td>
<td>51<br>
</td>
<td>84<br>
</td>
<td>42%<br>
</td>
</tr>
<tr>
<td>Angina<a href="#section-">   *</a>
</td>
<td>(7.7)<br>
</td>
<td>(12.8)<br>
</td>
<td>(0.002)<br>
</td>
</tr>
<tr>
<td>Coronary<br>
</td>
<td>78<br>
</td>
<td>103<br>
</td>
<td>27%<br>
</td>
</tr>
<tr class="Last">
<td>Revascularization<a href="#section-">   *</a>
</td>
<td>(11.8)<br>
</td>
<td>(15.7)<br>
</td>
<td>(0.033)<br>
</td>
</tr>
</tbody>
</table>
<a href="#section-">   *</a>     Total patients with these events<br><br><br><a href="#section-"></a>Amlodipine Effects in Patients with Congestive Heart 
Failure<p class="First">Amlodipine has been compared to placebo in four 8–12 week studies 
of patients with NYHA class II/III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, involving a total of 697 
patients. In these studies, there was no evidence of worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> 
based on measures of exercise tolerance, NYHA classification, symptoms, or LVEF. 
In a long-term (follow-up at least 6 months, mean 13.8 months) 
placebo-controlled mortality/morbidity study of amlodipine 5–10 mg in 1153 
patients with NYHA classes III (n=931) or IV (n=222) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> on stable 
doses of diuretics, digoxin, and ACE inhibitors, amlodipine had no effect on the 
primary endpoint of the study which was the combined endpoint of all-cause 
mortality and cardiac morbidity (as defined by life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, 
<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or hospitalization for worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), or 
on NYHA classification, or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Total combined all-cause 
mortality and cardiac morbidity events were 222/571 (39%) for patients on 
amlodipine and 246/583 (42%) for patients on placebo; the cardiac morbid events 
represented about 25% of the endpoints in the study.</p>
<p>Another study (PRAISE-2) randomized patients with NYHA class III (80%) or IV 
(20%) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> without clinical symptoms or objective evidence of 
underlying ischemic disease, on stable doses of ACE inhibitor (99%), digitalis 
(99%) and diuretics (99%), to placebo (n=827) or amlodipine (n=827) and followed 
them for a mean of 33 months. There was no statistically significant difference 
between amlodipine and placebo in the primary endpoint of all cause mortality 
(95% confidence limits from 8% reduction to 29% increase on amlodipine). With 
amlodipine there were more reports of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.</p>
<a href="#section-"></a><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5"></a><p></p>
<a href="http://"></a>Clinical Studies with Atorvastatin <a href="http://"></a><a href="http://"></a>Prevention of Cardiovascular Disease<p class="First">In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the 
effect of atorvastatin on fatal and non-fatal coronary heart disease was 
assessed in 10,305 hypertensive patients 40–80 years of age (mean of 63 years), 
without a previous <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and with TC levels less than or equal to 251 mg/dl (6.5 
mmol/l). Additionally all patients had at least 3 of the following 
cardiovascular risk factors: male gender (81.1%), age greater than 55 years (84.5%), 
smoking (33.2%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (24.3%), history of CHD in a first-degree relative 
(26%), TC:HDL greater than 6 (14.3%), <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> (5.1%), left 
<span class="product-label-link" type="condition" conceptid="4145489" conceptname="Ventricular hypertrophy">ventricular hypertrophy</span> (14.4%), prior cerebrovascular event (9.8%), specific 
ECG abnormality (14.3%), <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>/<span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span> (62.4%)]. In this double-blind, 
placebo-controlled study, patients were treated with anti-hypertensive therapy 
(Goal BP less than 140/90 mm Hg for non-diabetic patients; less than 130/80 mm Hg for 
diabetic patients) and allocated to either atorvastatin 10 mg daily (n=5168) or 
placebo (n=5137), using a covariate adaptive method which took into account the 
distribution of nine baseline characteristics of patients already enrolled and 
minimized the imbalance of those characteristics across the groups. Patients 
were followed for a median duration of 3.3 years.</p>
<p>The effect of 10 mg/day of atorvastatin on lipid levels was similar to that 
seen in previous clinical trials.</p>
<p>Atorvastatin significantly reduced the rate of coronary events [either fatal 
coronary heart disease (46 events in the placebo group vs. 40 events in the 
atorvastatin group) or nonfatal MI (108 events in the placebo group vs. 60 
events in the atorvastatin group)] with a relative risk reduction of 36% [(based 
on incidences of 1.9% for atorvastatin vs. 3.0% for placebo), p=0.0005 (see <a href="#figure3">Figure 3</a>)]. The risk reduction was consistent regardless of 
age, smoking status, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, or presence of renal dysfunction. The effect of 
atorvastatin was seen regardless of baseline LDL levels. Due to the small number 
of events, results for women were inconclusive.</p>
<p><span class="Bold">Figure 3: Effect of Atorvastatin 10 mg/day on Cumulative 
Incidence of Nonfatal<br><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> or Coronary Heart Disease <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> 
(in ASCOT-LLA)</span></p>
<div class="Figure"><img alt="image of figure 3 graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Figure%203%20graph.jpg"></div>
<br><p>Atorvastatin also significantly decreased the relative risk for 
revascularization procedures by 42%. Although the reduction of fatal and 
non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> did not reach a pre-defined significance level (p 0.01), a 
favorable trend was observed with a 26% relative risk reduction (incidences of 
1.7% for atorvastatin and 2.3% for placebo). There was no significant difference 
between the treatment groups for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to cardiovascular causes (p=0.51) or 
noncardiovascular causes (p=0.17).</p>
<p>In the Collaborative Atorvastatin <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Study (CARDS), the effect of 
atorvastatin on cardiovascular disease (CVD) endpoints was assessed in 2838 
subjects (94% White, 68% male), ages 40–75 with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> based on WHO 
criteria, without prior history of cardiovascular disease and with LDL less than or equal to 160 
mg/dL and TG less than or equal to 600 mg/dL. In addition to <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, subjects had 1 or more of the 
following risk factors: current smoking (23%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (80%), <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> 
(30%), or <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span> (9%) or macroalbuminuria (3%). No subjects on 
hemodialysis were enrolled in the study. In this multicenter, 
placebo-controlled, double-blind clinical trial, subjects were randomly 
allocated to either atorvastatin 10 mg daily (1429) or placebo (1411) in a 1:1 
ratio and were followed for a median duration of 3.9 years. The primary endpoint 
was the occurrence of any of the major cardiovascular events: myocardial 
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, coronary revascularization, or 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The primary analysis was the time to first occurrence of the primary 
endpoint.</p>
<p>Baseline characteristics of subjects were: mean age of 62 years, mean 
HbA<span class="Sub">1c</span> 7.7%; median LDL-C 120 mg/dL; median TC 207 mg/dL; 
median TG 151 mg/dL; median HDL-C 52 mg/dL. </p>
<p>The effect of atorvastatin 10 mg/day on lipid levels was similar to that seen 
in previous clinical trials.</p>
<p>Atorvastatin significantly reduced the rate of major cardiovascular events 
(primary endpoint events) (83 events in the atorvastatin group vs 127 events in 
the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI 
(0.48,0.83) (p=0.001) (see <a href="#figure4">Figure 4</a>). An effect of 
atorvastatin was seen regardless of age, sex, or baseline lipid levels.</p>
<p><span class="Bold">Figure 4. Effect of Atorvastatin 10 mg/day on Time to 
Occurrence of Major<br>Cardiovascular Events (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, acute CHD 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>,<br>coronary revascularization, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) in 
CARDS.</span></p>
<br><p><img alt="image of figure 4 graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Figure%204%20graph.jpg"></p>
<p>Atorvastatin significantly reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by 48% (21 events in 
the atorvastatin group vs. 39 events in the placebo group), HR 0.52, 95% CI 
(0.31, 0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the 
atorvastatin group vs. 64 events in the placebo group), HR 0.58, 95.1% CI (0.39, 
0.86) (p=0.007). There was no significant difference between the treatment 
groups for angina, revascularization procedures, and acute CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>There were 61 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the atorvastatin group vs. 82 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the placebo 
group, (HR 0.73, p=0.059).</p>
<p>In the Treating to New Targets Study (TNT), the effect of LIPITOR 80 mg/day 
vs. LIPITOR 10 mg/day on the reduction in cardiovascular events was assessed in 
10,001 subjects (94% white, 81% male, 38% greater than or equal to 65 years) with clinically evident 
coronary heart disease who had achieved a target LDL-C level less than 130 mg/dL after 
completing an 8-week, open-label, run-in period with LIPITOR 10 mg/day. Subjects 
were randomly assigned to either 10 mg/day or 80 mg/day of LIPITOR and followed 
for a median duration of 4.9 years. The primary endpoint was the time-to-first 
occurrence of any of the following major cardiovascular events (MCVE): <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due 
to CHD, non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and fatal 
and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The mean LDL-C, TC, TG, non-HDL, and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
levels at 12 weeks were 73, 145, 128, 98, and 47 mg/dL during treatment with 80 
mg of LIPITOR and 99, 177, 152, 129, and 48 mg/dL during treatment with 10 mg of 
LIPITOR.</p>
<p>Treatment with LIPITOR 80 mg/day significantly reduced the rate of MCVE (434 
events in the 80mg/day group vs. 548 events in the 10 mg/day group) with a 
relative risk reduction of 22%, HR 0.78, 95% CI (0.69,0.89), p=0.0002 (see <a href="#Fig5">Figure5</a> and <a href="#Table5">Table 5</a>). The overall risk 
reduction was consistent regardless of age (less than 65, greate than or equal to 65) or gender.</p>
<p><span class="Bold">Figure 5. Effect of LIPITOR 80 mg/day vs. 10 mg/day on Time to 
Occurrence of<br>Major Cardiovascular Events (TNT)</span></p>
<p><img alt="image of figure 5 graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Figure%205%20graph.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6"></a><p></p>
<a name="i5f6d4b5e-b0d8-4d99-8d24-b9b582043fa5"></a><table width="100%">
<caption><span>TABLE 5. Overview of Efficacy Results in TNT</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Endpoint<br><br><br></span></td>
<td><span class="Bold">Atorvastatin 10<br>mg<br>(N=5006)<br></span></td>
<td><span class="Bold"><br></span></td>
<td>
<span class="Bold">Atorvastatin 80</span><br><span class="Bold">
mg</span><br><span class="Bold">
(N=4995)</span><span class="Bold"></span><br><span class="Bold"></span>
</td>
<td><br></td>
<td><span class="Bold"><br>HR<a href="http://SPLForm_DrugListing.xhtml#footnote-8">*</a> (95%CI)<br><br></span></td>
</tr>
<tr>
<td>
<span class="Bold">PRIMARY ENDPOINT</span><br>
</td>
<td>n<br>
</td>
<td>(%)<br>
</td>
<td>n<br>
</td>
<td>(%)<br>
</td>
<td><br></td>
</tr>
<tr>
<td>First major cardiovascular endpoint<br>
</td>
<td>548<br>
</td>
<td>(10.9)<br>
</td>
<td>434<br>
</td>
<td>(8.7)<br>
</td>
<td>0.78 (0.69, 0.89)<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Components of the Primary Endpoint</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>
</td>
<td>127<br>
</td>
<td>(2.5)<br>
</td>
<td>101<br>
</td>
<td>(2.0)<br>
</td>
<td>0.80 (0.61, 103)<br>
</td>
</tr>
<tr>
<td>Non-fatal, non-procedure related MI<br>
</td>
<td>308<br>
</td>
<td>(6.2)<br>
</td>
<td>243<br>
</td>
<td>(4.9)<br>
</td>
<td>0.78 (0.66, 0.93)<br>
</td>
</tr>
<tr>
<td>Resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span><br>
</td>
<td>26<br>
</td>
<td>(0.5)<br>
</td>
<td>25<br>
</td>
<td>(0.5)<br>
</td>
<td>0.96 (0.56, 1.67)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> (fatal and non-fatal)<br>
</td>
<td>155<br>
</td>
<td>(3.1)<br>
</td>
<td>117<br>
</td>
<td>(2.3)<br>
</td>
<td>0.75 (0.59, 0.96)<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">SECONDARY ENDPOINTS</span><a href="#footnote-9">†</a>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>First CHF with hospitalization<br>
</td>
<td>164<br>
</td>
<td>(3.3)<br>
</td>
<td>122<br>
</td>
<td>(2.4)<br>
</td>
<td>0.74 (0.59, 0.94)<br>
</td>
</tr>
<tr>
<td>First PVD endpoint<br>
</td>
<td>282<br>
</td>
<td>(5.6)<br>
</td>
<td>275<br>
</td>
<td>(5.5)<br>
</td>
<td>0.97 (0.83, 1.15)<br>
</td>
</tr>
<tr>
<td>First CABG or other coronary <br>revascularization procedure<a href="#footnote-10">‡</a>
</td>
<td>904<br>
</td>
<td>(18.1)<br>
</td>
<td>667<br>
</td>
<td>(13.4)<br>
</td>
<td>0.72 (0.65, 0.80)<br>
</td>
</tr>
<tr>
<td>First documented angina endpoint<a href="#footnote-10">‡</a>
</td>
<td>615<br>
</td>
<td>12.3)<br>
</td>
<td>545<br>
</td>
<td>(10.9)<br>
</td>
<td>0.88 (0.79, 0.99)<br>
</td>
</tr>
<tr>
<td>All cause mortality<br>
</td>
<td>282<br>
</td>
<td>(5.6)<br>
</td>
<td>284<br>
</td>
<td>(5.7)<br>
</td>
<td>1.01 (0.85, 1.19)<br>
</td>
</tr>
<tr>
<td>
<span class="Bold">Components of all cause mortality</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>
</td>
<td>155<br>
</td>
<td>(3.1)<br>
</td>
<td>126<br>
</td>
<td>(2.5)<br>
</td>
<td>0.81 (0.64, 1.03)<br>
</td>
</tr>
<tr>
<td>Noncardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>
</td>
<td>127<br>
</td>
<td>(2.5)<br>
</td>
<td>158<br>
</td>
<td>(3.2)<br>
</td>
<td>1.25 (0.99, 1.57)<br>
</td>
</tr>
<tr>
<td>Cancer <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>
</td>
<td>75<br>
</td>
<td>(1.5)<br>
</td>
<td>85<br>
</td>
<td>(1.7)<br>
</td>
<td>1.13 (0.83, 1.55)<br>
</td>
</tr>
<tr>
<td>Other non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>
</td>
<td>43<br>
</td>
<td>(0.9)<br>
</td>
<td>58<br>
</td>
<td>(1.2)<br>
</td>
<td>1.35 (0.91, 2.00)<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>, homicide and other traumatic <br>non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br>
</td>
<td>9<br>
</td>
<td>(0.2)<br>
</td>
<td>15<br>
</td>
<td>(0.3)<br>
</td>
<td>1.67 (0.73, 3.82)<br>
</td>
</tr>
</tbody>
</table>HR=hazard ratio, CHD =coronary heart disease; CI=confidence interval; MI=<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; 
CHF=<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; <br>CV=cardiovascular; PVD=<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>; CABG=coronary artery bypass 
graft<br>Confidence intervals for the Secondary Endpoints were not adjusted for multiple 
comparisons.<br><span class="Bold"><a href="http://SPLForm_DrugListing.xhtml#footnote-8">*</a>     </span>Atorvastatin 80 mg: atorvastatin 10 mg<br><a href="http://SPLForm_DrugListing.xhtml#footnote-9">†</a>     Secondary endpoints not included in primary endpoint<br><a href="http://SPLForm_DrugListing.xhtml#footnote-10">‡</a>     Component of other secondary endpoints<br><br><br><p class="First">Of the events that comprised the primary efficacy endpoint, treatment with 
LIPITOR 80 mg/day significantly reduced the rate of non-fatal, non-procedure 
related MI and fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but not CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or resuscitated 
<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (<a href="#Table5">Table 5</a>). Of the predefined secondary 
endpoints, treatment with LIPITOR 80 mg/day significantly reduced the rate of 
coronary revascularization, angina, and hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, but 
not <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. The reduction in the rate of CHF with 
hospitalization was only observed in the 8% of patients with a prior history of 
CHF.</p>
<p>There was no significant difference between the treatment groups for 
all-cause mortality (<a href="#Table5">Table 5</a>). The proportions of subjects 
who experienced cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including the components of CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and 
fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, were numerically smaller in the LIPITOR 80 mg group than in the 
LIPITOR 10 mg treatment group. The proportions of subjects who experienced 
noncardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically larger in the LIPITOR 80 mg group than 
in the LIPITOR 10 mg treatment group.</p>
<p>In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering 
Study (IDEAL), treatment with LIPITOR 80 mg/day was compared to treatment with 
simvastatin 20–40 mg/day in 8,888 subjects up to 80 years of age with a history 
of CHD to assess whether reduction in CV risk could be achieved. Patients were 
mainly male (81%), white (99%) with an average age of 61.7 years, and an average 
LDL-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this 
prospective, randomized, open-label, blinded endpoint (PROBE) trial with no 
run-in period, subjects were followed for a median duration of 4.8 years. The 
mean LDL-C, TC, TG, HDL, and non-HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels at Week 12 were 78, 145, 
115, 45, and 100 mg/dL during treatment with 80 mg of LIPITOR and 105, 179, 142, 
47, and 132 mg/dL during treatment with 20–40 mg of simvastatin.</p>
<p>There was no significant difference between the treatment groups for the 
primary endpoint, the rate of first major coronary event (fatal CHD, nonfatal MI 
and resuscitated <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>): 411 (9.3%) in the LIPITOR 80 mg/day group vs. 
463 (10.4%) in the simvastatin 20–40 mg/day group, HR 0.89, 95% CI ( 0.78, 
1.01), p=0.07. </p>
<p>There were no significant differences between the treatment groups for 
all-cause mortality: 366 (8.2%) in the LIPITOR 80 mg/day group vs. 374 (8.4%) in 
the simvastatin 20–40 mg/day group. The proportions of subjects who experienced 
CV or non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were similar for the LIPITOR 80 mg group and the simvastatin 
20–40 mg group. </p>
<a href="http://"></a><a href="http://"></a>Atorvastatin Studies in <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous 
Familial and Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (Fredrickson Types IIa and 
IIb)<p>Atorvastatin reduces total-C, LDL-C, VLDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG, and 
increases HDL-C in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. 
Therapeutic response is seen within 2 weeks, and maximum response is usually 
achieved within 4 weeks and maintained during chronic therapy.</p>
<p>Atorvastatin is effective in a wide variety of patient populations with 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, with and without <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, in men and women, and in 
the elderly.</p>
<p>In two multicenter, placebo-controlled, dose-response studies in patients 
with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, atorvastatin given as a single dose over 6 weeks, 
significantly reduced total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG (pooled results are provided 
in <a href="#table6">Table 6</a>). </p>
<a name="icd041548-e3d0-46bd-821f-d5f1cad0fa4f"></a><table width="90%">
<caption><span>Table 6. Dose-Response in Patients With Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Adjusted Mean Percent Change From Baseline)*</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Dose</span><br>
</td>
<td>
<span class="Bold">N      </span><br>
</td>
<td>
<span class="Bold">TC</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><br>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
<td>
<span class="Bold">Non-HDL-C/ HDL-C</span><br>
</td>
</tr>
<tr>
<td>Placebo     <br>
</td>
<td>21      <br>
</td>
<td>4<br>
</td>
<td>4<br>
</td>
<td>3<br>
</td>
<td>10<br>
</td>
<td>-3<br>
</td>
<td>7<br>
</td>
</tr>
<tr>
<td>10<br>
</td>
<td>22      <br>
</td>
<td>-29<br>
</td>
<td>-39<br>
</td>
<td>-32<br>
</td>
<td>-19<br>
</td>
<td>6<br>
</td>
<td>-34<br>
</td>
</tr>
<tr>
<td>20<br>
</td>
<td>20      <br>
</td>
<td>-33<br>
</td>
<td>-43<br>
</td>
<td>-35<br>
</td>
<td>-26<br>
</td>
<td>9<br>
</td>
<td>-41<br>
</td>
</tr>
<tr>
<td>40<br>
</td>
<td>21     <br>
</td>
<td>-37<br>
</td>
<td>-50<br>
</td>
<td>-42<br>
</td>
<td>-29<br>
</td>
<td>6<br>
</td>
<td>-45<br>
</td>
</tr>
<tr class="Last">
<td>80<br>
</td>
<td>23      <br>
</td>
<td>-45<br>
</td>
<td>-60<br>
</td>
<td>-50<br>
</td>
<td>-37<br>
</td>
<td>5<br>
</td>
<td>-53<br>
</td>
</tr>
</tbody>
</table>
<a href="#footnote-11">*</a>     Results are pooled from 2 dose-response studies.<br><br><br><p>In patients with <span class="Italics">Fredrickson</span> Types IIa and IIb 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipoproteinemia</span> pooled from 24 controlled trials, the median (25<span class="Sup">th</span> and 75<span class="Sup">th</span> percentile) percent changes 
from baseline in HDL-C for atorvastatin 10, 20, 40, and 80 mg were 6.4 (-1.4, 
14), 8.7 (0, 17), 7.8 (0, 16), and 5.1 (-2.7, 15), respectively. Additionally, 
analysis of the pooled data demonstrated consistent and significant decreases in 
total-C, LDL-C, TG, total-C/HDL-C, and LDL-C/HDL-C.</p>
<p>In three multicenter, double-blind studies in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, 
atorvastatin was compared to other statins. After randomization, patients were 
treated for 16 weeks with either atorvastatin 10 mg per day or a fixed dose of 
the comparative agent (<a href="#table7">Table 7</a>).</p>
<a name="i513e96c4-e40e-4d66-86dd-ffc7a59b25a6"></a><table width="100%">
<caption><span>Table 7. Mean Percent Change From Baseline at Endpoint (Double-Blind, Randomized, Active-Controlled Trials)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Treatment<br>(Daily Dose)<br></span></td>
<td><span class="Bold"><br>N<br></span></td>
<td><span class="Bold"><br>Total-C<br></span></td>
<td><span class="Bold"><br>LDL-C<br></span></td>
<td><span class="Bold"><br><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span><br></span></td>
<td><span class="Bold"><br>TG<br></span></td>
<td><span class="Bold"><br>HDL-C<br></span></td>
<td><span class="Bold">Non-HDL-C/<br>HDL-C<br></span></td>
</tr>
<tr>
<td>
<span class="Italics">Study 1</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Atorvastatin 10 mg</td>
<td>707<br>
</td>
<td>-27<a href="#footnote-12">*</a>
</td>
<td>-36<a href="#footnote-12">*</a>
</td>
<td>-28<a href="#footnote-12">*</a>
</td>
<td>-17<a href="#footnote-12">*</a>
</td>
<td>+7<br>
</td>
<td>-37<a href="#footnote-12">*</a>
</td>
</tr>
<tr>
<td>Lovastatin 20 mg<br>
</td>
<td>191<br>
</td>
<td>-19<br>
</td>
<td>-27<br>
</td>
<td>-20<br>
</td>
<td>-6<br>
</td>
<td>+7<br>
</td>
<td>-28<br>
</td>
</tr>
<tr>
<td>95% CI for Diff<a href="#footnote-13">†</a>
</td>
<td><br></td>
<td>-9.2, -6.5<br>
</td>
<td>-10.7, -7.1<br>
</td>
<td>-10.0, -6.5<br>
</td>
<td>-15.2, -7.1<br>
</td>
<td>-1.7, 2.0<br>
</td>
<td>-11.1, -7.1<br>
</td>
</tr>
<tr>
<td>
<span class="Italics">Study 2</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Atorvastatin 10 mg</td>
<td>222<br>
</td>
<td>-25<a href="#footnote-14">‡</a>
</td>
<td>-35<a href="#footnote-14">‡</a>
</td>
<td>-27<a href="#footnote-14">‡</a>
</td>
<td>-17<a href="#footnote-14">‡</a>
</td>
<td>+6<br>
</td>
<td>-36<a href="#footnote-14">‡</a>
</td>
</tr>
<tr>
<td>Pravastatin 20 mg<br>
</td>
<td>77<br>
</td>
<td>-17<br>
</td>
<td>-23<br>
</td>
<td>-17<br>
</td>
<td>-9<br>
</td>
<td>+8<br>
</td>
<td>-28<br>
</td>
</tr>
<tr>
<td>95% CI for Diff<a href="#footnote-13">†</a>
</td>
<td><br></td>
<td>-10.8, -6.1<br>
</td>
<td>-14.5, -8.2<br>
</td>
<td>-13.4, -7.4<br>
</td>
<td>-14.1, -0.7<br>
</td>
<td>-4.9, 1.6<br>
</td>
<td>-11.5, -4.1<br>
</td>
</tr>
<tr>
<td>
<span class="Italics">Study 3</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Atorvastatin 10 mg</td>
<td>132<br>
</td>
<td>-29<a href="#footnote-15">§</a>
</td>
<td>-37<a href="#footnote-15">§</a>
</td>
<td>-34<a href="#footnote-15">§</a>
</td>
<td>-23<a href="#footnote-15">§</a>
</td>
<td>+7<br>
</td>
<td>-39<a href="#footnote-15">§</a>
</td>
</tr>
<tr>
<td>Simvastatin 10 mg<br>
</td>
<td>45<br>
</td>
<td>-24<br>
</td>
<td>-30<br>
</td>
<td>-30<br>
</td>
<td>-15<br>
</td>
<td>+7<br>
</td>
<td>-33<br>
</td>
</tr>
<tr class="Last">
<td>95% CI for Diff<a href="#footnote-13">†</a>
</td>
<td><br></td>
<td>-8.7, -2.7<br>
</td>
<td>-10.1, -2.6<br>
</td>
<td>-8.0, -1.1<br>
</td>
<td>-15.1, -0.7<br>
</td>
<td>-4.3, 3.9<br>
</td>
<td>-9.6, -1.9<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-12">*</a>     Significantly different from lovastatin, ANCOVA, p less than or equal to 0.05 <br><a href="http://SPLForm_DrugListing.xhtml#footnote-13">†</a>     A negative value for the 95% CI for the difference between treatments favors 
atorvastatin for all except HDL-C, for which a positive value favors 
atorvastatin. If the range does not include 0, this indicates a statistically 
significant difference.<br><a href="http://SPLForm_DrugListing.xhtml#footnote-14">‡</a>     Significantly different from pravastatin, ANCOVA, p less than or equal to 0.05 <br><a href="http://SPLForm_DrugListing.xhtml#footnote-15">§</a>     <br>   Significantly different from simvastatin, ANCOVA, p less than or equal to 0.05 <br><br><p>The impact on clinical outcomes of the differences in lipid-altering effects 
between treatments shown in Table 7 is not known. Table 7 does not contain data 
comparing the effects of atorvastatin 10 mg and higher doses of lovastatin, 
pravastatin, and simvastatin. The drugs compared in the studies summarized in 
the table are not necessarily interchangeable. </p>
<a href="http://"></a><a href="http://"></a>Atorvastatin Effects in <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> 
(Fredrickson Type IV)<p>The response to atorvastatin in 64 patients with isolated 
<span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> treated across several clinical trials is shown in the 
table below (Table 8). For the atorvastatin-treated patients, median (min, max) 
baseline TG level was 565 (267–1502).</p>
<a name="iff159af7-266d-44e8-8f41-2a305424722e"></a><table width="100%">
<caption><span>Table 8. Combined Patients With Isolated Elevated TG: Median (min, max) 
Percent Changes From Baseline</span></caption>
<col align="left" width="16%">
<col align="center" width="21%">
<col align="center" width="21%">
<col align="center" width="21%">
<col align="center" width="21%">
<thead><tr class="First Last">
<th align="left"><br></th>
<th align="center">Placebo<br>(N=12)</th>
<th align="center">Atorvastatin 10 mg<br>(N=37)</th>
<th align="center">Atorvastatin 20 mg<br>(N=13)</th>
<th align="center">Atorvastatin 80 mg<br>(N=14)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Triglycerides</td>
<td align="center">-12.4 (-36.6, 82.7)</td>
<td align="center">-41.0 (-76.2, 49.4)</td>
<td align="center">-38.7 (-62.7, 29.5)</td>
<td align="center">-51.8 (-82.8, 41.3)</td>
</tr>
<tr>
<td align="left">Total-C</td>
<td align="center">-2.3 (-15.5, 24.4)</td>
<td align="center">-28.2 (-44.9, -6.8)</td>
<td align="center">-34.9 (-49.6, -15.2)</td>
<td align="center">-44.4 (-63.5, -3.8)</td>
</tr>
<tr>
<td align="left">LDL-C</td>
<td align="center">3.6 (-31.3, 31.6)</td>
<td align="center">-26.5 (-57.7, 9.8)</td>
<td align="center">-30.4 (-53.9, 0.3)</td>
<td align="center">-40.5 (-60.6, -13.8)</td>
</tr>
<tr>
<td align="left">HDL-C</td>
<td align="center">3.8 (-18.6, 13.4)</td>
<td align="center">13.8 (-9.7, 61.5)</td>
<td align="center">11.0 (-3.2, 25.2)</td>
<td align="center">7.5 (-10.8, 37.2)</td>
</tr>
<tr>
<td align="left">VLDL-C</td>
<td align="center">-1.0 (-31.9, 53.2)</td>
<td align="center">-48.8 (-85.8, 57.3)</td>
<td align="center">-44.6 (-62.2, -10.8)</td>
<td align="center">-62.0 (-88.2, 37.6)</td>
</tr>
<tr class="Last">
<td align="left">non-HDL-C</td>
<td align="center">-2.8 (-17.6, 30.0)</td>
<td align="center">-33.0 (-52.1, -13.3)</td>
<td align="center">-42.7 (-53.7, -17.4)</td>
<td align="center">-51.5 (-72.9, -4.3)</td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a>Atorvastatin Effects in Dysbetalipoproteinemia 
(Fredrickson Type III)<p>The results of an open-label crossover study of atorvastatin in 
16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with 
dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III) are 
shown in the table below (Table 9).</p>
<a name="i0de15340-0460-4ca5-8cba-b62449d9e80e"></a><table width="100%">
<caption><span>Table 9. Open-Label Crossover Study of 16 Patients With 
Dysbetalipoproteinemia (Fredrickson Type III)</span></caption>
<col align="left" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead>
<tr class="First">
<th align="left"><br></th>
<th align="center"><br></th>
<th align="center" colspan="2">Median % Change (min, max)</th>
</tr>
<tr class="Last">
<th align="left"><br></th>
<th align="center">Median (min, max) at<br>Baseline (mg/dL)</th>
<th align="center">Atorvastatin 10 mg</th>
<th align="center">Atorvastatin 80 mg</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Total-C</td>
<td align="center">442 (225, 1320)</td>
<td align="center">-37 (-85, 17)</td>
<td align="center">-58 (-90, -31)</td>
</tr>
<tr>
<td align="left">Triglycerides</td>
<td align="center">678 (273, 5990)</td>
<td align="center">-39 (-92, -8)</td>
<td align="center">-53 (-95, -30)</td>
</tr>
<tr>
<td align="left">IDL-C + VLDL-C</td>
<td align="center">215 (111, 613)</td>
<td align="center">-32 (-76, 9)</td>
<td align="center">-63 (-90, -8)</td>
</tr>
<tr class="Last">
<td align="left">non-HDL-C</td>
<td align="center">411 (218, 1272)</td>
<td align="center">-43 (-87, -19)</td>
<td align="center">-64 (-92, -36)</td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Atorvastatin Effects in Homozygous Familial 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span><p>In a study without a concurrent control group, 29 patients ages 6 
to 37 years with homozygous FH received maximum daily doses of 20 to 80 mg of 
atorvastatin. The mean LDL-C reduction in this study was 18%. Twenty-five 
patients with a reduction in LDL-C had a mean response of 20% (range of 7% to 
53%, median of 24%); the remaining 4 patients had 7% to 24% increases in LDL-C. 
Five of the 29 patients had absent LDL-receptor function. Of these, 2 patients 
also had a portacaval shunt and had no significant reduction in LDL-C. The 
remaining 3 receptor-negative patients had a mean LDL-C reduction of 22%.</p>
<a href="http://"></a><a href="http://"></a>Atorvastatin Effects in Heterozygous Familial 
Hypercholesterolemic Pediatric Patients<p>In a double-blind, placebo-controlled study followed by an 
open-label phase, 187 boys and postmenarchal girls 10–17 years of age (mean age 
14.1 years) with heterozygous FH or severe <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, were randomized 
to atorvastatin (n=140) or placebo (n=47) for 26 weeks and then all received 
atorvastatin for 26 weeks. Inclusion in the study required 1) a baseline LDL-C 
level ≥ 190 mg/dL or 2) a baseline LDL-C level ≥ 160 mg/dL and positive family 
history of FH or documented premature cardiovascular disease in a first- or 
second-degree relative. The mean baseline LDL-C value was 218.6 mg/dL (range: 
138.5–385.0 mg/dL) in the atorvastatin group compared to 230.0 mg/dL (range: 
160.0–324.5 mg/dL) in placebo group. The dosage of atorvastatin (once daily) was 
10 mg for the first 4 weeks and up-titrated to 20 mg if the LDL-C level was &gt; 
130 mg/dL. The number of atorvastatin-treated patients who required up-titration 
to 20 mg after Week 4 during the double-blind phase was 80 (57.1%).</p>
<p>Atorvastatin significantly decreased plasma levels of total-C, LDL-C, 
triglycerides, and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B during the 26 week double-blind phase (see 
<a href="#table10">Table 10</a>).</p>
<a href="http://"></a><a name="i0928bd47-e20a-4a58-801a-c301b2ec19c8"></a><table width="100%">
<caption><span>Table 10. Lipid-altering Effects of Atorvastatin in Adolescent Boys and 
Girls with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> or Severe 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Mean Percent Change From Baseline at Endpoint in 
Intention-to-Treat Population)</span></caption>
<col align="left" width="14%">
<col align="center" width="7%">
<col align="center" width="14%">
<col align="center" width="14%">
<col align="center" width="14%">
<col align="center" width="14%">
<col align="center" width="23%">
<thead><tr class="First Last">
<th align="left">DOSAGE</th>
<th align="center">N</th>
<th align="center">Total-C</th>
<th align="center">LDL-C</th>
<th align="center">HDL-C</th>
<th align="center">TG</th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">Apolipoprotein</span> B</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Placebo</td>
<td align="center">47</td>
<td align="center">-1.5</td>
<td align="center">-0.4</td>
<td align="center">-1.9</td>
<td align="center">1.0</td>
<td align="center">0.7</td>
</tr>
<tr class="Last">
<td align="left">Atorvastatin</td>
<td align="center">140</td>
<td align="center">-31.4</td>
<td align="center">-39.6</td>
<td align="center">2.8</td>
<td align="center">-12.0</td>
<td align="center">-34.0</td>
</tr>
</tbody>
</table>
<p>The mean achieved LDL-C value was 130.7 mg/dL (range: 70.0–242.0 mg/dL) in 
the atorvastatin group compared to 228.5 mg/dL (range: 152.0–385.0 mg/dL) in the 
placebo group during the 26 week double-blind phase.</p>
<p>The safety and efficacy of atorvastatin doses above 20 mg have not been 
studied in controlled trials in children. The long-term efficacy of atorvastatin 
therapy in childhood to reduce morbidity and mortality in adulthood has not been 
established.</p>
<a href="http://"></a><a href="http://"></a>Clinical Study of Combined Amlodipine and 
Atorvastatin in Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span><p>In a double-blind, placebo-controlled study, a total of 1660 
patients with co-morbid <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> received once daily 
treatment with eight dose combinations of amlodipine and atorvastatin (5/10, 
10/10, 5/20, 10/20, 5/40, 10/40, 5/80, or 10/80 mg), amlodipine alone (5 mg or 
10 mg), atorvastatin alone (10 mg, 20 mg, 40 mg, or 80 mg) or placebo<span class="Bold">.</span> In addition to concomitant <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, 
15% of the patients had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, 22% were smokers and 14% had a 
positive family history of cardiovascular disease. At eight weeks, all eight 
combination-treatment groups of amlodipine and atorvastatin demonstrated 
statistically significant dose-related reductions in systolic blood pressure 
(SBP), diastolic blood pressure (DBP) and LDL-C compared to placebo, with no 
overall modification of effect of either component on SBP, DBP and LDL-C (<a href="#table11">Table 11</a>).</p>
<a href="http://"></a><a name="i1b875958-4f93-452c-8f8a-cc70b24b253b"></a><table width="100%">
<caption><span>Table 11. Efficacy in Terms of Reduction in Blood Pressure and 
LDL-C</span></caption>
<col align="center" width="16%">
<col align="center" width="19%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="13%">
<col align="center" width="13%">
<tbody class="Headless">
<tr class="First"><td align="center">Efficacy of the Combined Treatments in 
Reducing Systolic BP</td></tr>
<tr>
<td align="center">Parameter / Analysis</td>
<td align="center">ATO 0 mg</td>
<td align="center">ATO 10 mg</td>
<td align="center">ATO 20 mg</td>
<td align="center">ATO 40 mg</td>
<td align="center">ATO 80 mg</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Mean change<br>(mmHg)</td>
<td align="center">-3.0</td>
<td align="center">-4.5</td>
<td align="center">-6.2</td>
<td align="center">-6.2</td>
<td align="center">-6.4</td>
</tr>
<tr>
<td align="center">AML 0 mg</td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Difference versus<br>placebo (mmHg)</td>
<td align="center">-</td>
<td align="center">-1.5</td>
<td align="center">-3.2</td>
<td align="center">-3.2</td>
<td align="center">-3.4</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Mean change<br>(mmHg)</td>
<td align="center">-12.8</td>
<td align="center">-13.7</td>
<td align="center">-15.3</td>
<td align="center">-12.7</td>
<td align="center">-12.2</td>
</tr>
<tr>
<td align="center">AML 5 mg</td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Difference versus<br>placebo (mmHg)</td>
<td align="center">-9.8</td>
<td align="center">-10.7</td>
<td align="center">-12.3</td>
<td align="center">-9.7</td>
<td align="center">-9.2</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Mean change<br>(mmHg)</td>
<td align="center">-16.2</td>
<td align="center">-15.9</td>
<td align="center">-16.1</td>
<td align="center">-16.3</td>
<td align="center">-17.6</td>
</tr>
<tr>
<td align="center">AML 10 mg</td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Difference versus<br>placebo (mmHg)</td>
<td align="center">-13.2</td>
<td align="center">-12.9</td>
<td align="center">-13.1</td>
<td align="center">-13.3</td>
<td align="center">-14.6</td>
</tr>
<tr><td align="center"><br></td></tr>
<tr><td align="center">Efficacy of the Combined Treatments in Reducing 
Diastolic BP</td></tr>
<tr>
<td align="center">Parameter / Analysis</td>
<td align="center">ATO 0 mg</td>
<td align="center">ATO 10 mg</td>
<td align="center">ATO 20 mg</td>
<td align="center">ATO 40 mg</td>
<td align="center">ATO 80 mg</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Mean change<br>(mmHg)</td>
<td align="center">-3.3</td>
<td align="center">-4.1</td>
<td align="center">-3.9</td>
<td align="center">-5.1</td>
<td align="center">-4.1</td>
</tr>
<tr>
<td align="center">AML 0 mg</td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Difference versus<br>placebo (mmHg)</td>
<td align="center">-</td>
<td align="center">-0.8</td>
<td align="center">-0.6</td>
<td align="center">-1.8</td>
<td align="center">-0.8</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Mean change<br>(mmHg)</td>
<td align="center">-7.6</td>
<td align="center">-8.2</td>
<td align="center">-9.4</td>
<td align="center">-7.3</td>
<td align="center">-8.4</td>
</tr>
<tr>
<td align="center">AML 5 mg</td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Difference versus<br>placebo (mmHg)</td>
<td align="center">-4.3</td>
<td align="center">-4.9</td>
<td align="center">-6.1</td>
<td align="center">-4.0</td>
<td align="center">-5.1</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Mean change<br>(mmHg)</td>
<td align="center">-10.4</td>
<td align="center">-9.1</td>
<td align="center">-10.6</td>
<td align="center">-9.8</td>
<td align="center">-11.1</td>
</tr>
<tr>
<td align="center">AML 10 mg</td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center">Difference versus<br>placebo (mmHg)</td>
<td align="center">-7.1</td>
<td align="center">-5.8</td>
<td align="center">-7.3</td>
<td align="center">-6.5</td>
<td align="center">-7.8</td>
</tr>
<tr><td align="center"><br></td></tr>
<tr><td align="center">Efficacy of the Combined Treatments in Reducing LDL-C 
(% change)</td></tr>
<tr>
<td align="center">Parameter / Analysis</td>
<td align="center">ATO 0 mg</td>
<td align="center">ATO 10 mg</td>
<td align="center">ATO 20 mg</td>
<td align="center">ATO 40 mg</td>
<td align="center">ATO 80 mg</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center">AML 0 mg</td>
<td align="center">Mean % change</td>
<td align="center">-1.1</td>
<td align="center">-33.4</td>
<td align="center">-39.5</td>
<td align="center">-43.1</td>
<td align="center">-47.2</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center">AML 5 mg</td>
<td align="center">Mean % change</td>
<td align="center">-0.1</td>
<td align="center">-38.7</td>
<td align="center">-42.3</td>
<td align="center">-44.9</td>
<td align="center">-48.4</td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="center">AML 10 mg</td>
<td align="center">Mean % change</td>
<td align="center">-2.5</td>
<td align="center">-36.6</td>
<td align="center">-38.6</td>
<td align="center">-43.2</td>
<td align="center">-49.1</td>
</tr>
<tr class="Last">
<td align="center"><br></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
</tbody>
</table>
<br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-7"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CADUET (amlodipine and atorvastatin) is indicated in patients for 
whom treatment with both amlodipine and atorvastatin is appropriate.</p>
<a href="http://"></a><a href="http://"></a>Amlodipine1. 
<span><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span><span class="Bold">:</span> 
Amlodipine is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone 
or in combination with other antihypertensive agents; 
2. 
<span><span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span> (CAD)</span><br><span class="Underline">Chronic Stable Angina:</span> Amlodipine is indicated for the 
treatment of chronic stable angina. Amlodipine may be used alone or in 
combination with other antianginal or antihypertensive agents;<br><span class="Underline">Vasospastic Angina (Prinzmetal's or <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Variant Angina</span>):</span> 
Amlodipine is indicated for the treatment of confirmed or suspected vasospastic 
angina. Amlodipine may be used as monotherapy or in combination with other 
antianginal drugs.<br><span class="Underline">Angiographically Documented 
CAD:</span> In patients with recently documented CAD by angiography and without 
<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or an <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> less than 40%, amlodipine is indicated to reduce 
the risk of hospitalization due to angina and to reduce the risk of a coronary 
revascularization procedure. <p>AND</p>
<a href="http://"></a><a href="http://"></a>Atorvastatin<p>Therapy with lipid-altering agents should be only one component 
of multiple risk factor intervention in individuals at significantly increased 
risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug 
therapy is recommended as an adjunct to diet when the response to a diet 
restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures 
alone has been inadequate. In patients with CHD or multiple risk factors for 
CHD, the atorvastatin component of CADUET can be started simultaneously with 
diet restriction.</p>1. 
<span>Prevention of Cardiovascular Disease:</span> In 
adult patients without clinically evident coronary heart disease, but with 
multiple risk factors for coronary heart disease such as age, smoking, 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, low HDL-C, or a family history of early coronary heart disease, 
atorvastatin is indicated to:
<ul>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> 
</li>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> 
</li>
<li>Reduce the risk for revascularization procedures and angina </li>
</ul>
<br>In 
patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and without clinically evident coronary heart 
disease, but with multiple risk factors for coronary heart disease such as 
<span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, smoking, or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, LIPITOR is indicated to:
<ul>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> 
</li>
<li>Reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; </li>
</ul>
<br>In patients with clinically evident 
coronary heart disease, LIPITOR is indicated to:
<ul>
<li>Reduce the risk of non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> 
</li>
<li>Reduce the risk of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> 
</li>
<li>Reduce the risk for revascularization procedures 
</li>
<li>Reduce the risk of hospitalization for CHF 
</li>
<li>Reduce the risk of angina </li>
</ul>
<br>2. 
<span>Heterozygous Familial and Nonfamilial 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></span><span class="Bold">:</span> Atorvastatin is indicated as an 
adjunct to diet to reduce elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span>, and TG levels and to 
increase HDL-C in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (heterozygous 
familial and nonfamilial) and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (<span class="Italics">Fredrickson</span> Types IIa and IIb); 
3. 
<span>Elevated Serum TG Levels</span><span class="Bold">:</span> Atorvastatin is indicated as an adjunct to diet for the 
treatment of patients with elevated serum TG levels (<span class="Italics">Fredrickson</span> Type IV); 
4. 
<span>Primary Dysbetalipoproteinemia</span><span class="Bold">:</span> Atorvastatin is indicated for the treatment of patients with 
primary dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III) 
who do not respond adequately to diet; 
5. 
<span><span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></span><span class="Bold">:</span> Atorvastatin is indicated to reduce total-C and LDL-C in 
patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> as an adjunct to other 
lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are 
unavailable; 
6. 
<span>Pediatric Patients</span><span class="Bold">:</span> 
Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and 
<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">apo B</span> levels in boys and postmenarchal girls, 10 to 17 years of age, with 
<span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> if after an adequate trial of diet 
therapy the following findings are present:
<ol>
<li>LDL-C remains greater than or equal to 190 mg/dL or 
</li>
<li>LDL-C remains greater than or equal to 160 mg/dL and:
<ul>
<li>there is a positive family history of premature cardiovascular disease or 
</li>
<li>two or more other CVD risk factors are present in the pediatric patients. 
</li>
</ul>
</li>
</ol>
<p>The antidyslipidemic component of CADUET has not been studied in conditions 
where the major lipoprotein abnormality is elevation of chylomicrons (<span class="Italics">Fredrickson</span> Types I and V). </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-8"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CADUET contains atorvastatin and is therefore contraindicated in 
patients with active liver disease, which may include unexplained persistent 
elevations in hepatic transaminase levels.</p>
<p>CADUET is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any 
component of this medication.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pregnancy and Lactation<p>CADUET contains atorvastatin and is therefore contraindicated in 
women who are pregnant or may become pregnant. The atorvastatin component of 
CADUET may cause fetal harm when administered to a pregnant woman. Serum 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
or <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> derivatives are essential for fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> 
is a chronic process and discontinuation of lipid-lowering drugs during 
pregnancy should have little impact on the outcome of long-term therapy of 
primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>.</p>
<p>There are no adequate and well-controlled studies of atorvastatin use during 
pregnancy; however in rare reports congenital anomalies were observed following 
intrauterine exposure to statins. In rat and rabbit animal reproduction studies, 
atorvastatin revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. CADUET, WHICH INCLUDES 
ATORVASTATIN, SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH 
PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL 
HAZARDS. If the patient becomes pregnant while taking this drug, therapy should 
be discontinued immediately and the patient apprised of the potential hazard to 
the fetus (see <span class="Bold"><a href="#precautions_pregnancy">PRECAUTIONS, 
Pregnancy</a></span>).</p>
<p>It is not known whether atorvastatin or amlodipine are excreted into human 
milk; however a small amount of another statin does pass into breast milk. 
Because statins have the potential for serious adverse reactions in nursing 
infants, women taking CADUET should not breastfeed their infants (see <span class="Bold"><a href="#precautions_nursing">PRECAUTIONS, Nursing 
Mothers</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-9"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a>Skeletal Muscle<p class="First"><span class="Bold">Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with acute renal 
failure secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported with the atorvastatin 
component of CADUET and with other statins.</span> A history of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> 
may be a risk factor for the development of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Such patients merit 
closer monitoring for skeletal muscle effect<span class="Bold">s.</span></p>
<p>The atorvastatin component of CADUET, like other statins, occasionally causes 
<span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, defined as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in conjunction with 
increases in creatine phosphokinase (CPK) values &gt;10 times ULN. The 
concomitant use of higher doses of atorvastatin with certain drugs such as 
cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole 
and HIV protease inhibitors) increases the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> should be considered in any patient with diffuse <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, muscle 
<span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or marked elevation of CPK. Patients should be advised 
to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly 
if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. CADUET therapy should be discontinued if 
markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with statins is increased with 
concurrent administration of cyclosporine, fibric acid derivatives, 
erythromycin, clarithromycin, combination of ritonavir plus saquinavir or 
lopinavir plus ritonavir, niacin, or azole antifungals. Physicians considering 
combined therapy with CADUET and fibric acid derivatives, erythromycin, 
clarithromycin, a combination of ritonavir plus saquinavir or lopinavir plus 
ritonavir, immunosuppressive drugs, azole antifungals, or lipid-modifying doses 
of niacin should carefully weigh the potential benefits and risks and should 
carefully monitor patients for any signs or symptoms of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, 
or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly during the initial months of therapy and during any 
periods of upward dosage titration of either drug. Lower starting and 
maintenance doses of atorvastatin should be considered when taken concomitantly 
with the aforementioned drugs (see <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug 
Interactions</a></span>). Periodic creatine phosphokinase (CPK) determinations 
may be considered in such situations, but there is no assurance that such 
monitoring will prevent the occurrence of severe <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. </p>
<p>Prescribing recommendations for atorvastatin, a component of CADUET, and 
interacting agents are summarized in Table 12 (see <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a>, <a href="#precautions_drug_interactions">PRECAUTIONS, Drug Interactions</a>,</span> 
and <span class="Bold"><a href="#clinical_pharmacology">CLINICAL 
PHARMACOLOGY</a></span>).</p>
<a href="http://"></a><a name="id0c8fb1b-e321-4a33-89dc-f3d074e847be"></a><table width="60%">
<caption><span>TABLE 12 Atorvastatin Drug Interactions Associated with Increased Risk 
of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">Interacting Agents</th>
<th align="left">Prescribing Recommendations </th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Cyclosporine</td>
<td align="left">Do not exceed 10 mg atorvastatin daily</td>
</tr>
<tr class="Last">
<td align="left">Clarithromycin, Itraconazole, HIV protease inhibitors 
(ritonavir plus saquinavir or lopinavir plus ritonavir,)</td>
<td align="left">Caution when exceeding doses &gt; 20mg atorvastatin daily. The 
lowest dose necessary should be used.</td>
</tr>
</tbody>
</table>
<p><span class="Bold">In patients taking CADUET, therapy should be temporarily 
withheld or discontinued in any patient with an acute, serious condition 
suggestive of a <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or having a risk factor predisposing to the development 
of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (e.g., severe acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, major surgery, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, severe metabolic, endocrine and electrolyte 
disorders, and uncontrolled <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>).</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Liver Dysfunction<p>Statins, like the atorvastatin component of CADUET and like some 
other lipid-lowering therapies, have been associated with biochemical 
abnormalities of liver function. <span class="Bold">Persistent elevations (&gt;3 
times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum 
transaminases occurred in 0.7% of patients who received atorvastatin in clinical 
trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 
10, 20, 40, and 80 mg, respectively.</span></p>
<p>In clinical trials in patients taking the atorvastatin component of CADUET, 
the following has been observed. One patient in clinical trials developed 
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. Increases in liver function tests (LFT) in other patients were not 
associated with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other clinical signs or symptoms. Upon dose 
reduction, drug interruption, or discontinuation, transaminase levels returned 
to or near pretreatment levels without sequelae. Eighteen of 30 patients, with 
persistent LFT elevations continued treatment with a reduced dose of 
atorvastatin. </p>
<p>It is recommended that liver function tests be performed prior to and at 12 
weeks following both the initiation of therapy and any elevation of dose, and 
periodically (e.g., semiannually) thereafter. Liver enzyme changes generally 
occur in the first 3 months of treatment with the atorvastatin component of 
CADUET. Patients who develop increased transaminase levels should be monitored 
until the abnormalities resolve. Should an increase in ALT or AST of &gt;3 times 
ULN persist, reduction of dose or withdrawal of CADUET is recommended. </p>
<p>Active liver disease or unexplained persistent transaminase elevations are 
contraindications to the use of CADUET (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Increased Angina and/or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span><p>Worsening angina and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> can develop 
after starting or increasing the dose of amlodipine, particularly in patients 
with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-10"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span><p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is possible, particularly in patients 
with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>. Because of the gradual onset of action, acute 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is unlikely.</p>
<a href="http://"></a><a href="http://"></a>Beta-Blocker Withdrawal<p>The amlodipine component of CADUET is not a beta-blocker and 
therefore gives no protection against the dangers of abrupt beta-blocker 
withdrawal; any such withdrawal should be by gradual reduction of the dose of 
beta-blocker.</p>
<a href="http://"></a><a href="http://"></a>Endocrine Function<p>Statins, such as the atorvastatin component of CADUET interfere 
with <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and theoretically might blunt adrenal and/or gonadal 
steroid production. Clinical studies have shown that atorvastatin does not 
reduce basal plasma cortisol concentration or impair adrenal reserve. The 
effects of statins on male fertility have not been studied in adequate numbers 
of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal 
women are unknown. Use caution when administering a statin with drugs that may 
decrease the levels or activity of endogenous steroid hormones, such as 
ketoconazole, spironolactone, and cimetidine.</p>
<a href="http://"></a><a href="http://"></a>CNS Toxicity<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Brain <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> was seen in a female dog treated with 
atorvastatin calcium for 3 months at a dose equivalent to 120 mg 
atorvastatin/kg/day. Brain <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and optic nerve vacuolation were seen in 
another female dog that was sacrificed in moribund condition after 11 weeks of 
escalating doses of atorvastatin calcium equivalent to up to 280 mg 
atorvastatin/kg/day. The 120 mg/kg dose of atorvastatin resulted in a systemic 
exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0–24 
hours) based on the maximum human dose of 80 mg/day. A single <span class="product-label-link" type="condition" conceptid="4198075" conceptname="Tonic seizure">tonic convulsion</span> 
was seen in each of 2 male dogs (one treated with atorvastatin calcium at a dose 
equivalent to 10 mg atorvastatin/kg/day and one at a dose equivalent to 120 mg 
atorvastatin/kg/day) in a 2-year study. No CNS lesions have been observed in 
mice after chronic treatment for up to 2 years at doses of atorvastatin calcium 
equivalent to up to 400 mg atorvastatin/kg/day or in rats at doses equivalent to 
up to 100 mg atorvastatin/kg/day. These doses were 6 to 11 times (mouse) and 8 
to 16 times (rat) the human AUC (0–24) based on the maximum recommended human 
dose of 80 mg atorvastatin/day. </p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and 
mononuclear cell infiltration of perivascular spaces, have been observed in dogs 
treated with other statins. A chemically similar drug in this class produced 
optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in 
clinically normal dogs in a dose-dependent fashion at a dose that produced 
plasma drug levels about 30 times higher than the mean drug level in humans 
taking the highest recommended dose.</p>
<a href="http://"></a><a href="http://"></a>Use in Patients with Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or TIA<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>In a post-hoc analysis of the <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention by Aggressive 
Reduction in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels (SPARCL) study where atorvastatin 80 mg vs. 
placebo was administered in 4,731 subjects without CHD who had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA 
within the preceding 6 months, a higher incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was seen 
in the atorvastatin 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 
33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of 
fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was similar across treatment groups (17 vs. 18 for the 
atorvastatin and placebo groups, respectively). The incidence of nonfatal 
<span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was significantly higher in the atorvastatin group (38, 1.6%) 
as compared to the placebo group (16, 0.7%). Some baseline characteristics, 
including hemorrhagic and lacunar <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> on study entry, were associated with a 
higher incidence of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> in the atorvastatin group (see <span class="Bold"><a href="#ARTACC">ADVERSE REACTIONS, The Atorvastatin Component of 
CADUET</a></span>). </p>
<a href="http://"></a><a href="http://"></a>Information for Patients<p>Because of the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> with statins, the drug class to 
which the atorvastatin component of CADUET belongs, advise patients to promptly 
report unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if 
accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. </p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Drug Interactions<p>Data from a drug-drug interaction study involving 10 mg of 
amlodipine and 80 mg of atorvastatin in healthy subjects indicate that the 
pharmacokinetics of amlodipine are not altered when the drugs are 
coadministered. The effect of amlodipine on the pharmacokinetics of atorvastatin 
showed no effect on the Cmax: 91% (90% confidence interval: 80 to 103%), but the 
AUC of atorvastatin increased by 18% (90% confidence interval: 109 to 127%) in 
the presence of amlodipine, which was not clinically meaningful.</p>
<p>No drug interaction studies have been conducted with CADUET and other drugs, 
although studies have been conducted in the individual amlodipine and 
atorvastatin components, as described below:</p>
<a href="http://"></a><a href="http://"></a>Studies with Amlodipine<p><span class="Italics">In vitro</span> data in human plasma indicate 
that amlodipine has no effect on the protein binding of drugs tested (digoxin, 
phenytoin, warfarin, and indomethacin).</p>
<p><span class="Bold">Cimetidine:</span> Co-administration of amlodipine with 
cimetidine did not alter the pharmacokinetics of amlodipine.</p>
<p><span class="Bold">Maalox® (antacid):</span> Co-administration of the antacid 
Maalox with a single dose of amlodipine had no significant effect on the 
pharmacokinetics of amlodipine.</p>
<p><span class="Bold">Sildenafil:</span> A single 100 mg dose of sildenafil 
(Viagra®) in subjects with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> had no effect on the 
pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were 
used in combination, each agent independently exerted its own blood pressure 
lowering effect.</p>
<p><span class="Bold">Digoxin:</span> Co-administration of amlodipine with digoxin 
did not change serum digoxin levels or digoxin renal clearance in normal 
volunteers.</p>
<p><span class="Bold">Ethanol (alcohol):</span> Single and multiple 10 mg doses of 
amlodipine had no significant effect on the pharmacokinetics of ethanol.</p>
<p><span class="Bold">Warfarin:</span> Co-administration of amlodipine with 
warfarin did not change the warfarin <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> response time.</p>
<p>In clinical trials, amlodipine has been safely administered with thiazide 
diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting 
nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal 
anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.</p>
<a href="http://"></a><a href="http://"></a>Studies with Atorvastatin<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with statins is increased 
with concurrent administration of fibric acid derivatives, lipid-modifying doses 
of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV 
protease inhibitors, and itraconazole) (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a>,</span> and <span class="Bold"><a href="#clinical_pharmacology">CLINICAL 
PHARMACOLOGY</a></span>).</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">Strong Inhibitors of CYP 3A4:</span> 
Atorvastatin is metabolized by cytochrome P450 3A4. Concomitant administration 
of atorvastatin with strong inhibitors of CYP 3A4 can lead to increases in 
plasma concentrations of atorvastatin. The extent of interaction and 
potentiation of effects depends on the variability of effect on CYP 3A4.</p>  
<span class="Bold">Clarithromycin: </span>Atorvastatin AUC was significantly 
increased with concomitant administration of atorvastatin 80 mg with 
clarithromycin (500 mg twice daily) compared to that of atorvastatin alone (see 
<span class="Bold"><a href="#clinical_pharmacology">CLINICAL 
PHARMACOLOGY</a></span>). Therefore, in patients taking clarithromycin, use 
caution when administering atorvastatin doses &gt; 20 mg (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a></span>, 
and <span class="Bold"><a href="#dosage_administration">DOSAGE AND 
ADMINISTRATION</a></span>). 
  
<span class="Bold">Combination of Protease Inhibitors: </span>Atorvastatin AUC 
was significantly increased with concomitant administration of atorvastatin 40 
mg with ritonavir plus saquinavir (400 mg twice daily) or atorvastatin 20 mg 
with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of 
atorvastatin alone (see <span class="Bold"><a href="#clinical_pharmacology">CLINICAL PHARMACOLOGY</a>)</span>. Therefore, in 
patients taking HIV protease inhibitors, use caution when administering 
atorvastatin doses ≥20 mg (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a></span>, and <span class="Bold"><a href="#dosage_administration">DOSAGE AND 
ADMINISTRATION</a></span>). 
  
<span class="Bold">Itraconazole: </span>Atorvastatin AUC was significantly 
increased with concomitant administration of atorvastatin 40 mg and itraconazole 
200 mg (see <span class="Bold"><a href="#clinical_pharmacology">CLINICAL 
PHARMACOLOGY</a></span>). Therefore, in patients taking itraconazole, use 
caution when administering atorvastatin doses ≥20 mg (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a></span>, and <span class="Bold"><a href="#dosage_administration">DOSAGE AND 
ADMINISTRATION</a></span>). <a href="http://"></a><a href="http://"></a><p><span class="Bold">Grapefruit juice:</span> Contains one or more 
components that inhibit CYP 3A4 and can increase plasma concentrations of 
atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 
liters per day).</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">Cyclosporine: </span>Atorvastatin and 
atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors 
of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of 
atorvastatin. Atorvastatin AUC was significantly increased with concomitant 
administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to 
that of atorvastatin alone (see <span class="Bold"><a href="#clinical_pharmacology">CLINICAL PHARMACOLOGY</a></span>). In cases where 
coadministration of atorvastatin with cyclosporine is necessary, the dose of 
atorvastatin should not exceed 10 mg (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a></span>). </p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">Rifampin or other Inducers of Cytochrome P450 
3A4: </span>Concomitant administration of atorvastatin with inducers of 
cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions 
in plasma concentrations of atorvastatin. Due to the dual interaction mechanism 
of rifampin, simultaneous co-administration of atorvastatin with rifampin is 
recommended, as delayed administration of atorvastatin after administration of 
rifampin has been associated with a significant reduction in atorvastatin plasma 
concentrations.</p>
<p><span class="Bold">Digoxin:</span> When multiple doses of atorvastatin and 
digoxin were coadministered, steady-state plasma digoxin concentrations 
increased by approximately 20%. Patients taking digoxin should be monitored 
appropriately.</p>
<p><span class="Bold">Oral Contraceptives:</span> Coadministration of atorvastatin 
and an oral contraceptive increased AUC values for norethindrone and ethinyl 
estradiol (see <span class="Bold"><a href="#clinical_pharmacology">CLINICAL 
PHARMACOLOGY</a></span>). These increases should be considered when selecting an 
oral contraceptive for a woman taking CADUET.</p>
<p><span class="Bold">Warfarin:</span> Atorvastatin had no clinically significant 
effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when administered to patients receiving chronic 
warfarin treatment.</p>
<a href="http://"></a><a href="http://"></a>Drug/Laboratory Test Interactions<p>None known.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>Rats and mice treated with amlodipine maleate in the diet for up 
to two years, at concentrations calculated to provide daily dosage levels of 
0.5, 1.25, and 2.5 mg amlodipine/kg/day, showed no evidence of a carcinogenic 
effect of the drug. For the mouse, the highest dose was, on a mg/m<span class="Sup">2</span> basis, similar to the maximum recommended human dose of 10 mg 
amlodipine/day<a href="#footnote-16">1</a>. 
For the rat, the highest dose level was, on a mg/m<span class="Sup">2</span> 
basis, about twice the maximum recommended human dose<a href="#footnote-16">1</a>.</p>
<p>Mutagenicity studies conducted with amlodipine maleate revealed no drug 
related effects at either the gene or chromosome levels.</p>
<p>There was no effect on the fertility of rats treated orally with amlodipine 
maleate (males for 64 days and females for 14 days prior to mating) at doses up 
to 10 mg amlodipine/kg/day (8 times<a href="#footnote-16">1</a> the 
maximum recommended human dose of 10 mg/day on a mg/m<span class="Sup">2</span> 
basis).</p>
<a href="#footnote-reference-16">1</a>Based on patent weight of 50 kg. <a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>In a 2-year carcinogenicity study with atorvastatin calcium in 
rats at dose levels equivalent to 10, 30, and 100 mg atorvastatin/kg/day, 2 rare 
tumors were found in muscle in high-dose females: in one, there was a 
<span class="product-label-link" type="condition" conceptid="4116201" conceptname="Rhabdomyosarcoma">rhabdomyosarcoma</span> and, in another, there was a <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcoma</span>. This dose represents 
a plasma AUC (0–24) value of approximately 16 times the mean human plasma drug 
exposure after an 80 mg oral dose.</p>
<p>A 2-year carcinogenicity study in mice given atorvastatin calcium at dose 
levels equivalent to 100, 200, and 400 mg atorvastatin/kg/day resulted in a 
significant increase in liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in high-dose males and <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">liver carcinomas</span> 
in high-dose females. These findings occurred at plasma AUC (0–24) values of 
approximately 6 times the mean human plasma drug exposure after an 80 mg oral 
dose. </p>
<p><span class="Italics">In vitro</span>, atorvastatin was not mutagenic or 
clastogenic in the following tests with and without metabolic activation: the 
Ames test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli</span>, the HGPRT forward mutation assay in 
Chinese hamster lung cells, and the chromosomal aberration assay in Chinese 
hamster lung cells. Atorvastatin was negative in the <span class="Italics">in 
vivo</span> mouse micronucleus test.</p>
<p>There were no effects on fertility when rats were given atorvastatin calcium 
at doses equivalent to up to 175 mg atorvastatin/kg/day (15 times the human 
exposure). There was <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> and <span class="product-label-link" type="condition" conceptid="40492473" conceptname="Aspermia">aspermia</span> in the epididymides of 2 of 10 rats 
treated with atorvastatin calcium at a dose equivalent to 100 mg 
atorvastatin/kg/day for 3 months (16 times the human AUC at the 80 mg dose); 
testis weights were significantly lower at 30 and 100 mg/kg/day and epididymal 
weight was lower at 100 mg/kg/day. Male rats given the equivalent of 100 mg 
atorvastatin/kg/day for 11 weeks prior to mating had decreased sperm motility, 
spermatid head concentration, and increased abnormal sperm. Atorvastatin caused 
no adverse effects on semen parameters, or reproductive organ histopathology in 
dogs given doses of atorvastatin calcium equivalent to 10, 40, or 120 mg 
atorvastatin/kg/day for two years.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pregnancy<a href="http://"></a><a href="http://"></a>Pregnancy Category X<p><span class="Bold">(see <a href="#contraindications">CONTRAINDICATIONS</a>)</span></p>
<p>CADUET contains atorvastatin and is therefore contraindicated in women who 
are pregnant or may become pregnant. The atorvastatin component of CADUET may 
cause fetal harm when administered to a pregnant woman. CADUET should be 
administered to women of child-bearing potential only when such patients are 
highly unlikely to conceive and have been informed of the potential hazards. If 
the woman becomes pregnant while taking CADUET, it should be discontinued 
immediately and the patient advised again as to the potential hazards to the 
fetus, and the lack of known clinical benefit with continued use during 
pregnancy.</p>
<p>Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> products are essential for fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a 
chronic process, and discontinuation of lipid-lowering drugs during pregnancy 
should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> 
therapy.</p>
<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other embryo/fetal toxicity was 
found when pregnant rats and rabbits were treated orally with amlodipine maleate 
at doses up to 10 mg amlodipine/kg/day (respectively 8 times<a href="#footnote-16">1</a> and 23 times<a href="#footnote-16">1</a> the 
maximum recommended human dose of 10 mg/day on a mg/m<span class="Sup">2</span> 
basis) during their respective periods of major organogenesis. However, litter 
size was significantly decreased (by about 50%) and the number of intrauterine 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was significantly increased (about 5-fold) in rats receiving amlodipine 
maleate at 10 mg amlodipine/kg/day for 14 days before mating and throughout 
mating and gestation. Amlodipine maleate has been shown to prolong both the 
gestation period and the duration of labor in rats at this dose. There are no 
adequate and well-controlled studies in pregnant women.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>There are no adequate and well-controlled studies of atorvastatin 
use during pregnancy. There have been rare reports of congenital anomalies 
following intrauterine exposure to statins. In a review of about 100 
prospectively followed pregnancies in women exposed to other statins, the 
incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and fetal 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed the rate expected in the general population. 
However, this study was only able to exclude a three-to-four-fold increased risk 
of congenital anomalies over background incidence. In 89% of these cases, drug 
treatment started before pregnancy and stopped during the first trimester when 
pregnancy was identified.</p>
<p>Atorvastatin crosses the rat placenta and reaches a level in fetal liver 
equivalent to that of maternal plasma. Atorvastatin was not teratogenic in rats 
at doses of atorvastatin calcium equivalent to up to 300 mg atorvastatin/kg/day 
or in rabbits at doses of atorvastatin calcium equivalent to up to 100 mg 
atorvastatin/kg/day. These doses resulted in multiples of about 30 times (rat) 
or 20 times (rabbit) the human exposure based on surface area (mg/m<span class="Sup">2</span>).</p>
<p>In a study in rats given atorvastatin calcium at doses equivalent to 20, 100, 
or 225 mg atorvastatin/kg/day, from gestation day 7 through to lactation day 21 
(weaning), there was decreased pup survival at birth, neonate, weaning, and 
maturity for pups of mothers dosed with 225 mg/kg/day. Body weight was decreased 
on days 4 and 21 for pups of mothers dosed at 100 mg/kg/day; pup body weight was 
decreased at birth and at days 4, 21, and 91 at 225 mg/kg/day. Pup development 
was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 
mg/kg/day; pinnae detachment and eye opening at 225 mg/kg/day). These doses of 
atorvastatin correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the 
human AUC at 80 mg/day.</p>
<a href="http://"></a><a href="http://"></a>Labor and Delivery<p>No studies have been conducted in pregnant women on the effect of 
CADUET, amlodipine or atorvastatin on the mother or the fetus during labor or 
delivery, or on the duration of labor or delivery. Amlodipine has been shown to 
prolong the duration of labor in rats.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Nursing Mothers<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>It is not known whether the amlodipine component of CADUET is 
excreted in human milk.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>It is not known whether the atorvastatin component of CADUET is 
excreted in human milk, but a small amount of another drug in this class does 
pass into breast milk. Nursing rat pups taking atorvastatin had plasma and liver 
drug levels of 50% and 40%, respectively, of that in their mother's milk. Animal 
breast milk drug levels may not accurately reflect human breast milk levels. 
Because another drug in this class passes into human milk and because statins 
have a potential to cause serious adverse reactions in nursing infants, women 
taking CADUET, which includes atorvastatin, should be advised not to nurse their 
infants (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pediatric Use<p>There have been no studies conducted to determine the safety or 
effectiveness of CADUET in pediatric populations.</p>
<a href="http://"></a><a href="http://"></a>Studies with amlodipine<p>The effect of amlodipine on blood pressure in patients less than 
6 years of age is not known.</p>
<a href="http://"></a><a href="http://"></a>Studies with atorvastatin<p>Safety and effectiveness in patients 10–17 years of age with 
<span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> have been evaluated in controlled 
clinical trials of 6 months duration in adolescent boys and postmenarchal girls. 
Patients treated with atorvastatin had an adverse experience profile generally 
similar to that of patients treated with placebo, the most common adverse 
experiences observed in both groups, regardless of causality assessment, were 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="Bold">Doses greater than 20 mg have not been studied in 
this patient population.</span> In this limited controlled study, there was no 
significant effect on growth or sexual maturation in boys or on menstrual cycle 
length in girls. See <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical 
Studies</a></span> section; <span class="Bold"><a href="#adverse_reactions_pediatric">ADVERSE REACTIONS, Pediatric Patients</a>; 
and <a href="#dosage_administration_pediatric">DOSAGE AND ADMINISTRATION, 
Pediatric Patients (10–17 years of age) with Heterozygous Familial 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></a></span>. Adolescent females should be counseled on 
appropriate contraceptive methods while on atorvastatin therapy (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#precautions_pregnancy">PRECAUTIONS, Pregnancy</a></span>). 
<span class="Bold">Atorvastatin has not been studied in controlled clinical trials 
involving pre-pubertal patients or patients younger than 10 years of age.</span></p>
<p>Clinical efficacy with doses of atorvastatin up to 80 mg/day for 1 year have 
been evaluated in an uncontrolled study of patients with homozygous FH including 
8 pediatric patients. See <span class="Bold"><a href="#clinical_pharmacology_clinical_atorvastatin">CLINICAL PHARMACOLOGY, 
Clinical Studies, Atorvastatin Effects in Homozygous Familial 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></a></span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Geriatric Use<p>There have been no studies conducted to determine the safety or 
effectiveness of CADUET in geriatric populations.</p>
<a href="http://"></a><a href="http://"></a>In studies with amlodipine<p>Clinical studies of amlodipine did not include sufficient numbers 
of subjects aged 65 and over to determine whether they respond differently from 
younger subjects. Other reported clinical experience has not identified 
differences in responses between the elderly and younger patients. In general, 
dose selection of the amlodipine component of CADUET for an elderly patient 
should be cautious, usually starting at the low end of the dosing range, 
reflecting the greater frequency of decreased hepatic, renal, or cardiac 
function, and of concomitant disease or other drug therapy. Elderly patients 
have decreased clearance of amlodipine with a resulting increase of AUC of 
approximately 40–60%, and a lower initial dose may be required (see <span class="Bold"><a href="#dosage_administration">DOSAGE AND 
ADMINISTRATION</a></span>).</p>
<a href="http://"></a><a href="http://"></a>In studies with atorvastatin<p>Of the 39,828 patients who received LIPITOR in clinical studies, 
15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall 
differences in safety or effectiveness were observed between these subjects and 
younger subjects, and other reported clinical experience has not identified 
differences in responses between the elderly and younger patients, but greater 
sensitivity of some older adults cannot be ruled out. Advanced age (≥65 years) 
is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-11"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a>CADUET<p class="First">CADUET (amlodipine besylate/atorvastatin calcium) has been 
evaluated for safety in 1092 patients in double-blind placebo controlled studies 
treated for co-morbid <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. In general, treatment with 
CADUET was well tolerated. For the most part, adverse experiences have been mild 
or moderate in severity. In clinical trials with CADUET, no adverse experiences 
peculiar to this combination have been observed. Adverse experiences are similar 
in terms of nature, severity, and frequency to those reported previously with 
amlodipine and atorvastatin. </p>
<p>The following information is based on the clinical experience with amlodipine 
and atorvastatin.</p>
<a href="http://"></a><a href="http://"></a>The Amlodipine Component of CADUET<p>Amlodipine has been evaluated for safety in more than 11,000 
patients in U.S. and foreign clinical trials. In general, treatment with 
amlodipine was well tolerated at doses up to 10 mg daily. Most adverse reactions 
reported during therapy with amlodipine were of mild or moderate severity. In 
controlled clinical trials directly comparing amlodipine (N=1730) in doses up to 
10 mg to placebo (N=1250), discontinuation of amlodipine due to adverse 
reactions was required in only about 1.5% of patients and was not significantly 
different from placebo (about 1%). The most common side effects are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and 
<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. The incidence (%) of side effects which occurred in a dose related manner 
are as follows:</p>
<a name="icb1de0fd-38a4-40f1-8f80-428b033f2b00"></a><table width="100%">
<col align="left" width="24%">
<col align="center" width="19%">
<col align="center" width="19%">
<col align="center" width="19%">
<col align="center" width="19%">
<thead>
<tr class="First">
<th align="left">Adverse Event</th>
<th align="center" colspan="4">amlodipine</th>
</tr>
<tr class="Last">
<th align="left"><br></th>
<th align="center">2.5 mg<br>N=275</th>
<th align="center">5.0 mg<br>N=296</th>
<th align="center">10.0 mg<br>N=268</th>
<th align="center">Placebo<br>N=520</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="center">1.8</td>
<td align="center">3.0</td>
<td align="center">10.8</td>
<td align="center">0.6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">1.1</td>
<td align="center">3.4</td>
<td align="center">3.4</td>
<td align="center">1.5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td align="center">0.7</td>
<td align="center">1.4</td>
<td align="center">2.6</td>
<td align="center">0.0</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td align="center">0.7</td>
<td align="center">1.4</td>
<td align="center">4.5</td>
<td align="center">0.6</td>
</tr>
</tbody>
</table>
<p>Other adverse experiences which were not clearly dose related but which were 
reported with an incidence greater than 1.0% in placebo-controlled clinical 
trials include the following:</p>
<a href="http://"></a><a href="http://"></a>Placebo-Controlled Studies<a name="ie3475897-358f-4bc3-804f-9e31ebcfefdd"></a><table width="100%">
<col align="left" width="33%">
<col align="center" width="34%">
<col align="center" width="33%">
<thead><tr class="First Last">
<th align="left">Adverse Event</th>
<th align="center">amlodipine (%)<br>(N=1730)</th>
<th align="center">Placebo (%)<br>(N=1250)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">7.3</td>
<td align="center">7.8</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">4.5</td>
<td align="center">2.8</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">2.9</td>
<td align="center">1.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">1.6</td>
<td align="center">0.3</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">1.4</td>
<td align="center">0.6</td>
</tr>
</tbody>
</table>
<p>For several adverse experiences that appear to be drug and dose 
related, there was a greater incidence in women than men associated with 
amlodipine treatment as shown in the following table:</p>
<a name="i033f1964-3e45-4f21-83e1-42164d79091b"></a><table width="100%">
<col align="left" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead>
<tr class="First">
<th align="left">Adverse Event</th>
<th align="center" colspan="2">amlodipine</th>
<th align="center" colspan="2">Placebo</th>
</tr>
<tr class="Last">
<th align="left"><br></th>
<th align="center">M=%<br>(N=1218)</th>
<th align="center">F=%<br>(N=512)</th>
<th align="center">M=%<br>(N=914)</th>
<th align="center">F=%<br>(N=336)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="center">5.6</td>
<td align="center">14.6</td>
<td align="center">1.4</td>
<td align="center">5.1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td align="center">1.5</td>
<td align="center">4.5</td>
<td align="center">0.3</td>
<td align="center">0.9</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td align="center">1.4</td>
<td align="center">3.3</td>
<td align="center">0.9</td>
<td align="center">0.9</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">1.3</td>
<td align="center">1.6</td>
<td align="center">0.8</td>
<td align="center">0.3</td>
</tr>
</tbody>
</table>
<p>The following events occurred in ≤1% but &gt;0.1% of patients treated with 
amlodipine in controlled clinical trials or under conditions of open trials or 
marketing experience where a causal relationship is uncertain; they are listed 
to alert the physician to a possible relationship:</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (including ventricular 
<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, 
<span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, postural 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Bold">Central and Peripheral Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, 
<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, 
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>,<a href="#footnote-17">2</a> 
<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gingival 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>.</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>,<a href="#footnote-17">2</a> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, weight 
gain, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>.</p>
<p><span class="Bold">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, muscle 
<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>,<a href="#footnote-17">2</a> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Bold">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> (male<a href="#footnote-17">2</a> and female), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, 
<span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>.</p>
<p><span class="Bold">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>,<a href="#footnote-17">2</a> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, 
<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>,<a href="#footnote-17">2</a> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,<a href="#footnote-17">2</a> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, 
<span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Bold">Urinary System:</span> micturition frequency, micturition 
disorder, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>.</p>
<p><span class="Bold">Autonomic Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> 
increased.</p>
<p><span class="Bold">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>.</p>
<p><span class="Bold">Hemopoietic:</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, 
<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>The following events occurred in ≤0.1% of patients treated with amlodipine in 
controlled clinical trials or under conditions of open trials or marketing 
experience: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, pulse irregularity, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, skin 
discoloration, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, skin dryness, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, 
<span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, 
<span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, 
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, abnormal visual 
accommodation, and <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span>.</p>
<p>Other reactions occurred sporadically and cannot be distinguished from 
medications or concurrent disease states such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and 
angina.</p>
<p>Amlodipine therapy has not been associated with clinically significant 
changes in routine laboratory tests. No clinically relevant changes were noted 
in serum potassium, serum glucose, total triglycerides, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, uric acid, blood urea nitrogen, or creatinine.</p>
<p>In the CAMELOT and PREVENT studies (see <span class="Bold"><a href="#C_c_aml">CLINICAL PHARMACOLOGY Clinical Studies, Clinical Studies with 
Amlodipine</a></span><span class="Italics">)</span> the adverse event profile was 
similar to that reported previously (see above), with the most common adverse 
event being <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. </p>
<p>The following postmarketing event has been reported infrequently with 
amlodipine treatment where a causal relationship is uncertain: <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>. In 
postmarketing experience, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and hepatic enzyme elevations (mostly 
consistent with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>) in some cases severe enough to require 
hospitalization have been reported in association with use of amlodipine.</p>
<p>Amlodipine has been used safely in patients with chronic obstructive 
pulmonary disease, well-compensated <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, peripheral 
vascular disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4042056" conceptname="Lipids abnormal">abnormal lipid profiles</span>.</p>
<a href="#footnote-reference-17">2</a>These events occurred in less than 1% in placebo-controlled trials, but the 
incidence of these side effects was between 1% and 2% in all multiple dose 
studies. <a href="http://"></a><a href="http://"></a><a href="http://"></a>The Atorvastatin Component of CADUET <p>The following serious adverse reactions are discussed in greater 
detail in other sections of the label:<br><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal 
Muscle</a></span>)<br>Liver enzyme abnormalities (see <span class="Bold"><a href="#WarnLD">WARNINGS, Liver Dysfunction</a></span>)</p>
<a href="http://"></a><a href="http://"></a>Clinical Adverse Experiences<p>Because clinical trials are conducted under widely varying 
conditions, the adverse reaction rates observed in the clinical studies of a 
drug cannot be directly compared to rates in the clinical trials of another drug 
and may not reflect the rates observed in clinical practice.</p>
<p>In the LIPITOR placebo-controlled clinical trial database of 16,066 patients 
(8755 LIPITOR vs. 7311 placebo; age range 10–93 years, 39% women, 91% 
Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 
53 weeks, 9.7% of patients on LIPITOR and 9.5% of the patients on placebo 
discontinued due to adverse reactions regardless of causality. The five most 
common adverse reactions in patients treated with LIPITOR that led to treatment 
discontinuation and occurred at a rate greater than placebo were: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> 
(0.7%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.4%), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increase 
(0.4%), and hepatic enzyme increase (0.4%). </p>
<p>The most commonly reported adverse reactions (incidence ≥ 2% and greater than 
placebo) regardless of causality, in patients treated with LIPITOR in placebo 
controlled trials (n=8755) were: <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (8.3%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (6.9%), 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.8%), <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span> (6.0%), and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (5.7%). 
</p>
<p>Table 13 summarizes the frequency of clinical adverse reactions, regardless 
of causality, reported in ≥ 2% and at a rate greater than placebo in patients 
treated with LIPITOR (n=8755), from seventeen placebo-controlled trials. </p>
<a name="idb423d22-6333-4601-8b21-815a527923da"></a><table width="100%">
<caption><span>Table 13. Clinical adverse reactions occurring in ≥ 2% in patents treated with any dose of LIPITOR and at an incidence greater than placebo regardless of causality (% of patients). </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Adverse Reaction<a href="#footnote-18"></a></span><a href="#footnote-18">*</a>
</td>
<td><span class="Bold">Any dose<br>N=8755<br></span></td>
<td><span class="Bold">10 mg<br>N=3908<br></span></td>
<td><span class="Bold">20 mg<br>N=188<br></span></td>
<td><span class="Bold">40 mg<br>N=604<br></span></td>
<td><span class="Bold">80 mg<br>N=4055<br></span></td>
<td><span class="Bold">Placebo<br>N=7311<br></span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span><br>
</td>
<td>8.3<br>
</td>
<td>12.9<br>
</td>
<td>5.3<br>
</td>
<td>7.0<br>
</td>
<td>4.2<br>
</td>
<td>8.2<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span><br>
</td>
<td>6.9<br>
</td>
<td>8.9<br>
</td>
<td>11.7<br>
</td>
<td>10.6<br>
</td>
<td>4.3<br>
</td>
<td>6.5<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td>6.8<br>
</td>
<td>7.3<br>
</td>
<td>6.4<br>
</td>
<td>14.1<br>
</td>
<td>5.2<br>
</td>
<td>6.3<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span><br>
</td>
<td>6.0<br>
</td>
<td>8.5<br>
</td>
<td>3.7<br>
</td>
<td>9.3<br>
</td>
<td>3.1<br>
</td>
<td>5.9<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span><br>
</td>
<td>5.7<br>
</td>
<td>6.9<br>
</td>
<td>6.4<br>
</td>
<td>8.0<br>
</td>
<td>4.1<br>
</td>
<td>5.6<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>
</td>
<td>4.7<br>
</td>
<td>5.9<br>
</td>
<td>3.2<br>
</td>
<td>6.0<br>
</td>
<td>3.3<br>
</td>
<td>4.3<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td>4.0<br>
</td>
<td>3.7<br>
</td>
<td>3.7<br>
</td>
<td>7.1<br>
</td>
<td>3.8<br>
</td>
<td>3.5<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span><br>
</td>
<td>3.8<br>
</td>
<td>5.2<br>
</td>
<td>3.2<br>
</td>
<td>5.1<br>
</td>
<td>2.3<br>
</td>
<td>3.6<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasm</span><br>
</td>
<td>3.6<br>
</td>
<td>4.6<br>
</td>
<td>4.8<br>
</td>
<td>5.1<br>
</td>
<td>2.4<br>
</td>
<td>3.0<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span><br>
</td>
<td>3.5<br>
</td>
<td>3.6<br>
</td>
<td>5.9<br>
</td>
<td>8.4<br>
</td>
<td>2.7<br>
</td>
<td>3.1<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br>
</td>
<td>3.0<br>
</td>
<td>2.8<br>
</td>
<td>1.1<br>
</td>
<td>5.3<br>
</td>
<td>2.8<br>
</td>
<td>2.9<br>
</td>
</tr>
<tr class="Last">
<td>Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br>
</td>
<td>2.3<br>
</td>
<td>3.9<br>
</td>
<td>1.6<br>
</td>
<td>2.8<br>
</td>
<td>0.7<br>
</td>
<td>2.1<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-18">*</a>     Adverse Reaction greater than or equal to 2% in any dose greater than placebo<br><br><br><p>Other adverse reactions reported in placebo-controlled studies 
include:<br><span class="Italics">Body as a whole</span>: <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>; <span class="Italics">Digestive system:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, 
<span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>; <span class="Italics">Musculoskeletal 
system</span>: <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; 
<span class="Italics">Metabolic and nutritional system</span>: transaminases 
increase, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, blood alkaline phosphatase increase, 
creatine phosphokinase increase, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; <span class="Italics">Nervous 
system</span>: <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span>; <span class="Italics">Respiratory system:</span> 
<span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; <span class="Italics">Skin and appendages</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="Italics">Special senses</span>: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="Italics">Urogenital system:</span> white blood cells urine positive. </p>
<a href="http://"></a><a href="http://"></a>Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT)<p>In ASCOT (see <span class="Bold"><a href="#clinical_pharmacology_clinical_studies">CLINICAL PHARMACOLOGY, Clinical 
Studies, Clinical Studies with Atorvastatin</a></span>) involving 10,305 
participants (age range 40–80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 
1.5% South Asians, 1.3% mixed/other) treated with atorvastatin 10 mg daily 
(n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group 
treated with atorvastatin was comparable to that of the group treated with 
placebo during a median of 3.3 years of follow-up.</p>
<a href="http://"></a><a href="http://"></a>Collaborative Atorvastatin <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Study 
(CARDS)<p>In CARDS (see <span class="Bold"><a href="#clinical_pharmacology_clinical_studies">CLINICAL PHARMACOLOGY, Clinical 
Studies, Clinical Studies with Atorvastatin</a></span>) involving 2838 subjects 
(age range 39–77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% 
Afro-Caribbean, 1.0% other)with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treated with LIPITOR 10 mg daily 
(n=1428) or placebo (n=1410), there was no difference in the overall frequency 
of adverse reactions or serious adverse reactions between the treatment groups 
during a median follow-up of 3.9 years. No cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> were 
reported.</p>
<a href="http://"></a><a href="http://"></a>Treating to New Targets Study (TNT)<p>In TNT (see <span class="Bold"><a href="#clinical_pharmacology_clinical_studies">CLINICAL PHARMACOLOGY, Clinical 
Studies</a></span>) involving 10,001 subjects (age range 29–78 years, 19% women; 
94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident 
CHD treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995), 
there were more serious adverse reactions and discontinuations due to adverse 
reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, 
respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, 
respectively) during a median follow-up of 4.9 years. Persistent transaminase 
elevations (≥3 × ULN twice within 4–10 days) occurred in 62 (1.3%) individuals 
with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. 
Elevations of CK (≥ 10 × ULN) were low overall, but were higher in the high-dose 
atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin 
group (6, 0.1%).</p>
<a href="http://"></a><a href="http://"></a>Incremental Decrease in Endpoints Through Aggressive 
Lipid Lowering Study (IDEAL)<p>In IDEAL (see <span class="Bold"><a href="#clinical_pharmacology_clinical_studies">CLINICAL PHARMACOLOGY, Clinical 
Studies</a></span>) involving 8,888 subjects (age range 26–80 years, 19% women; 
99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with LIPITOR 80 
mg/day (n=4439) or simvastatin 20–40 mg daily (n=4449), there was no difference 
in the overall frequency of adverse reactions or serious adverse reactions 
between the treatment groups during a median follow-up of 4.8 years.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention by Aggressive Reduction in 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels (SPARCL)<p>In SPARCL involving 4731 subjects (age range 21–92 years, 40% 
women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without 
clinically evident CHD but with a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack (TIA) 
within the previous 6 months treated with LIPITOR 80 mg (n=2365) or placebo 
(n=2366) for a median follow-up of 4.9 years, there was a higher incidence of 
persistent hepatic transaminase elevations (≥ 3 × ULN twice within 4–10 days) in 
the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK 
(&gt;10 × ULN) were rare, but were higher in the atorvastatin group (0.1%) 
compared to placebo (0.0%). <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> was reported as an adverse reaction in 144 
subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo 
group (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>).</p>
<p>In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of ischemic 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of 
<span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The 
incidence of fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> was similar between groups (17 LIPITOR vs. 
18 placebo). The incidence of non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span> was significantly 
greater in the atorvastatin group (38 non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>) as compared 
to the placebo group (16 non-fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>). Subjects who entered 
the study with a <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> appeared to be at increased risk for 
<span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> [7 (16%) LIPITOR vs. 2 (4%) placebo].</p>
<p>There were no significant differences between the treatment groups for 
all-cause mortality: 216 (9.1%) in the LIPITOR 80 mg/day group vs. 211 (8.9%) in 
the placebo group. The proportions of subjects who experienced cardiovascular 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically smaller in the LIPITOR 80 mg group (3.3%) than in the 
placebo group (4.1%). The proportions of subjects who experienced 
non-cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were numerically larger in the LIPITOR 80 mg group 
(5.0%) than in the placebo group (4.0%).</p>
<a href="http://"></a><a href="http://"></a>Postintroduction Reports with Atorvastatin<p>The following adverse reactions have been identified during 
postapproval use of the atorvastatin component of CADUET. Because these 
reactions are reported voluntarily from a population of uncertain size, it is 
not always possible to reliably estimate their frequency or establish a causal 
relationship to drug exposure.</p>
<p>Adverse reactions associated with atorvastatin therapy reported since market 
introduction, that are not listed above, regardless of causality assessment, 
include the following: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rashes</span> 
(including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and toxic epidermal 
necrolysis), <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, 
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pediatric Patients (ages 10–17 years)<p>In a 26-week controlled study in boys and postmenarchal girls 
(n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the 
safety and tolerability profile of atorvastatin 10 to 20 mg daily was generally 
similar to that of placebo (see <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical 
Studies</a></span> section and <span class="Bold"><a href="#precautions_pediatric">PRECAUTIONS, Pediatric Use</a></span>).</p>
<br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-12"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is no information on overdosage with CADUET in 
humans.</p>
<a href="http://"></a><a href="http://"></a>Information on Amlodipine <p>Single oral doses of amlodipine maleate equivalent to 40 mg 
amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Single oral amlodipine maleate doses equivalent to 4 or more mg 
amlodipine/kg in dogs (11 or more times the maximum recommended clinical dose on 
a mg/m<span class="Sup">2</span> basis) caused a marked peripheral vasodilation 
and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>Overdosage might be expected to cause excessive peripheral vasodilation with 
marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and possibly a <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span>. In humans, experience with 
intentional overdosage of amlodipine is limited. Reports of intentional 
overdosage include a patient who ingested 250 mg and was asymptomatic and was 
not hospitalized; another (120 mg) was hospitalized, underwent gastric lavage 
and remained normotensive; the third (105 mg) was hospitalized and had 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (90/50 mmHg) which normalized following plasma expansion. A patient 
who took 70 mg amlodipine and an unknown quantity of benzodiazepine in a <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> 
attempt developed <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> which was refractory to treatment and died the following 
day with abnormally high benzodiazepine plasma concentration. A case of 
accidental drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been documented in a 19-month-old male who ingested 
30 mg amlodipine (about 2 mg/kg). During the emergency room presentation, vital 
signs were stable with no evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, but a heart rate of 180 bpm. 
Ipecac was administered 3.5 hours after ingestion and on subsequent observation 
(overnight) no sequelae were noted.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should occur, begin active cardiac and respiratory monitoring. 
Perform frequent blood pressure measurements. Should <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occur, initiate 
cardiovascular support including elevation of the extremities and administration 
of fluids. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> remains unresponsive to these conservative measures, 
consider administration of vasopressors (such as phenylephrine) with specific 
attention to circulating volume and urine output. As amlodipine is highly 
protein bound, hemodialysis is not likely to be of benefit.</p>
<a href="http://"></a><a href="http://"></a>Information on Atorvastatin<p>There is no specific treatment for atorvastatin overdosage. In 
the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient should be treated symptomatically, and 
supportive measures instituted as required. Due to extensive drug binding to 
plasma proteins, hemodialysis is not expected to significantly enhance 
atorvastatin clearance. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-13"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage of CADUET must be individualized on the basis of both 
effectiveness and tolerance for each individual component in the treatment of 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>/angina and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>.</p>
<a href="http://"></a><a href="http://"></a>Amlodipine (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> or angina)<a href="http://"></a><a href="http://"></a>Adults<p>The usual initial antihypertensive oral dose of amlodipine is 5 
mg once daily with a maximum dose of 10 mg once daily. Small, fragile, or 
elderly individuals, or patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> may be started on 
2.5 mg once daily and this dose may be used when adding amlodipine to other 
antihypertensive therapy.</p>
<p>Dosage should be adjusted according to each patient's need. In general, 
titration should proceed over 7 to 14 days so that the physician can fully 
assess the patient's response to each dose level. Titration may proceed more 
rapidly, however, if clinically warranted, provided the patient is assessed 
frequently.</p>
<p>The recommended dose of amlodipine for chronic stable or vasospastic angina 
is 5–10 mg, with the lower dose suggested in the elderly and in patients with 
<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Most patients will require 10 mg for adequate effect. See 
<span class="Bold"><a href="#adverse_reactions">ADVERSE REACTIONS</a></span> 
section for information related to dosage and side effects.</p>
<p>The recommended dose range of amlodipine for patients with coronary artery 
disease is 5–10 mg once daily. In clinical studies the majority of patients 
required 10 mg (see <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical 
studies</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Children<p>The effective antihypertensive oral dose of amlodipine in 
pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily. Doses in excess 
of 5 mg daily have not been studied in pediatric patients (see <span class="Bold"><a href="#clinical_pharmacology">CLINICAL 
PHARMACOLOGY</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Atorvastatin (<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span>)<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Heterozygous Familial and 
Nonfamilial) and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (Fredrickson Types IIa and IIb)<p>The recommended starting dose of atorvastatin is 10 or 20 mg once 
daily. Patients who require a large reduction in LDL-C (more than 45%) may be 
started at 40 mg once daily. The dosage range of atorvastatin is 10 to 80 mg 
once daily. Atorvastatin can be administered as a single dose at any time of the 
day, with or without food. The starting dose and maintenance doses of 
atorvastatin should be individualized according to patient characteristics such 
as goal of therapy and response (see current <span class="Italics">NCEP 
Guidelines</span>). After initiation and/or upon titration of atorvastatin, 
lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted 
accordingly.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in 
Pediatric Patients (10–17 years of age)<p>The recommended starting dose of atorvastatin is 10 mg/day; the 
maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been 
studied in this patient population). Doses should be individualized according to 
the recommended goal of therapy (see current NCEP Pediatric Panel Guidelines<a href="#footnote-19">3</a>, <span class="Bold"><a href="#clinical_pharmacology">CLINICAL PHARMACOLOGY</a></span>, 
and <span class="Bold"><a href="#indications_usage">INDICATIONS AND 
USAGE</a></span>). Adjustments should be made at intervals of 4 weeks or 
more.</p>
<a href="#footnote-reference-19">3</a>National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program (NCEP): Highlights of the Report of 
the Expert Panel on Blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Levels in Children Adolescents. <span class="Italics">Pediatrics</span>. 89(3):495–501. 1992. <a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span><p>The dosage of atorvastatin in patients with homozygous FH is 10 
to 80 mg daily. Atorvastatin should be used as an adjunct to other 
lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such 
treatments are unavailable. Note: a 2.5/80 mg CADUET tablet is not available. 
Management of patients needing a 2.5/80 mg combination requires individual 
assessments of <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> and therapy with the individual components as a 
2.5/80 mg CADUET tablet is not available.</p>
<a href="http://"></a><a href="http://"></a>Concomitant Lipid Lowering Therapy<p>Atorvastatin may be used with bile acid resins. Monitor for signs 
of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in patients receiving the combination of statins and fibrates (see 
<span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal 
Muscle</a></span>, and <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug 
Interactions</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Dosage in Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><p><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span> does not affect the plasma concentrations nor LDL-C 
reduction of atorvastatin; thus, dosage adjustment in patients with renal 
dysfunction is not necessary (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a></span>, and <span class="Bold"><a href="#CPSP">CLINICAL PHARMACOLOGY, Specific 
Populations</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Dosage in Patients Taking Cyclosporine, 
Clarithromycin, Itraconazole, or a Combination of Ritonavir plus Saquinavir or 
Lopinavir plus Ritonavir<p>In patients taking cyclosporine, therapy should be limited to 
LIPITOR 10 mg once daily. In patients taking clarithromycin, itraconazole or in 
patients with HIV taking a combination of ritonavir plus saquinavir or lopinavir 
plus ritonavir, for doses of atorvastatin exceeding 20 mg, appropriate clinical 
assessment is recommended to ensure that the lowest dose necessary of 
atorvastatin is employed (see <span class="Bold"><a href="#warnings_skeletal">WARNINGS, Skeletal Muscle</a></span>, and <span class="Bold"><a href="#precautions_drug_interactions">PRECAUTIONS, Drug 
Interactions</a></span>).</p>
<a href="http://"></a><a href="http://"></a>CADUET<p>CADUET may be substituted for its individually titrated 
components. Patients may be given the equivalent dose of CADUET or a dose of 
CADUET with increased amounts of amlodipine, atorvastatin or both for additional 
antianginal effects, blood pressure lowering, or lipid lowering effect.</p>
<p>CADUET may be used to provide additional therapy for patients already on one 
of its components. As initial therapy for one indication and continuation of 
treatment of the other, the recommended starting dose of CADUET should be 
selected based on the continuation of the component being used and the 
recommended starting dose for the added monotherapy.</p>
<p>CADUET may be used to initiate treatment in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and 
either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina. The recommended starting dose of CADUET should be 
based on the appropriate combination of recommendations for the monotherapies. 
The maximum dose of the amlodipine component of CADUET is 10 mg once daily. The 
maximum dose of the atorvastatin component of CADUET is 80 mg once daily.</p>
<p>See above for detailed information related to the dosing and administration 
of amlodipine and atorvastatin.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CADUET tablets contain amlodipine besylate and atorvastatin 
calcium equivalent to amlodipine and atorvastatin in the dose strengths 
described below.</p>
<p>CADUET tablets are differentiated by tablet color/size and are engraved with 
"Pfizer" on one side and a unique number on the other side. CADUET tablets are 
supplied for oral administration in the following strengths and package 
configurations:</p>
<a name="i6defb0c4-283b-4eb2-83ab-fe6b9a7b4551"></a><table width="100%">
<caption><span>Table 14. CADUET Packaging Configurations</span></caption>
<col align="left" width="20%">
<col align="center" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<thead>
<tr class="First"><th align="left" colspan="5">CADUET</th></tr>
<tr class="Last">
<th align="left">Package<br>Configuration</th>
<th align="center">Tablet Strength<br>(amlodipine 
besylate/<br>atorvastatin calcium) mg</th>
<th align="left">NDC #</th>
<th align="left">Engraving</th>
<th align="left">Tablet Color</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><br></td>
<td align="center"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
<td align="left"><br></td>
</tr>
<tr>
<td align="left">Bottle of 30<br>
</td>
<td align="center">2.5/20</td>
<td align="left">54868-5672-0</td>
<td align="left">CDT 252</td>
<td align="left">White</td>
</tr>
<tr>
<td align="left">Bottle of 30</td>
<td align="center">2.5/40</td>
<td align="left">54868-5699-0<br>
</td>
<td align="left">CDT 254</td>
<td align="left">White</td>
</tr>
<tr>
<td align="left">Bottle of 30<br>Bottle of 90<br>
</td>
<td align="center">5/10</td>
<td align="left">54868-3287-0<br>54868-3287-1<br>
</td>
<td align="left">CDT 051</td>
<td align="left">White</td>
</tr>
<tr>
<td align="left">Bottle of 30<br>Bottle of 90<br>
</td>
<td align="center">5/20</td>
<td align="left">54868-1207-0<br>54868-1207-1<br>
</td>
<td align="left">CDT 052</td>
<td align="left">White</td>
</tr>
<tr>
<td align="left">Bottle of 30</td>
<td align="center">5/40</td>
<td align="left">54868-5179-0</td>
<td align="left">CDT 054</td>
<td align="left">White</td>
</tr>
<tr>
<td align="left">Bottle of 30</td>
<td align="center">5/80</td>
<td align="left">54868-5420-0<br>
</td>
<td align="left">CDT 058</td>
<td align="left">White</td>
</tr>
<tr>
<td align="left">Bottle of 30</td>
<td align="center">10/10</td>
<td align="left">54868-5567-0</td>
<td align="left">CDT 101</td>
<td align="left">Blue</td>
</tr>
<tr>
<td align="left">Bottle of 30<br>Bottle of 90<br>
</td>
<td align="center">10/20</td>
<td align="left">54868-5209-0<br>54868-5209-1<br>
</td>
<td align="left">CDT 102</td>
<td align="left">Blue</td>
</tr>
<tr>
<td align="left">Bottle of 30<br>Bottle of 90<br>
</td>
<td align="center">10/40</td>
<td align="left">54868-5200-0<br>54868-5200-1<br>
</td>
<td align="left">CDT 104</td>
<td align="left">Blue</td>
</tr>
<tr class="Last">
<td align="left">Bottle of 30<br>Bottle of 90<br>
</td>
<td align="center">10/80</td>
<td align="left">54868-5523-0<br>54868-5523-1<br>
</td>
<td align="left">CDT 108</td>
<td align="left">Blue</td>
</tr>
</tbody>
</table>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">Store at 25°C (77°F); excursions permitted to 
15–30°C (59–86°F) [see USP Controlled Room Temperature].</span></p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">Rx only</span></p>
<p>Manufactured by:<br><span class="Bold">Pfizer Ireland Pharmaceuticals</span><br>Dublin, Ireland</p>
<div class="Figure"><img alt="image of Pfizer logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Pfizer%20logo.jpg"></div>
<p></p>
<p><span class="Bold">LAB-0276-15.0</span></p>
<p><span class="Bold">January 2010</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<div class="Figure"><img alt="image of Caudet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Caudet.jpg"></div>
<p class="First">Read the patient information that comes with CADUET before you start taking 
it, and each time you get a refill. There may be new information. This 
information does not replace talking with your doctor about your condition or 
treatment. If you have any questions about CADUET, ask your doctor or 
pharmacist.</p>
<p><span class="Bold">What is CADUET?</span></p>
<p>CADUET is a prescription drug that combines Norvasc<span class="Sup">®</span> 
(amlodipine besylate) and Lipitor<span class="Sup">®</span> (atorvastatin calcium) 
in one pill. </p>
<p><span class="Bold">CADUET is used in adults who need both Norvasc and 
Lipitor.</span></p>
<p>Norvasc is used to treat:</p>
<ul>
<li>High blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) and 
</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (angina) and 
</li>
<li>Blocked arteries of the heart (<span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>) </li>
</ul>
<p>Lipitor is used to lower the levels of "bad" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides in 
your blood. It can also raise the levels of "good" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p>Lipitor is also used to lower the risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, certain 
types of heart surgery, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> in patients who have heart disease or 
risk factors for heart disease such as:</p>
<ul><li>age, smoking, high blood pressure, low HDL-C, heart disease in the family 
</li></ul>
<p>Lipitor can lower the risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patients with 
<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and risk factors such as: </p>
<ul><li>diabetic eye or kidney problems, smoking, or high blood pressure. </li></ul>
<p>CADUET has not been studied in children.</p>
<p><span class="Bold">Who should not use CADUET?</span></p>
<p><span class="Underline"><span class="Bold">Do not use CADUET if 
you</span>:</span></p>
<ul>
<li>Are pregnant or think you may be pregnant, or are planning to become 
pregnant. CADUET may harm your unborn baby. If you get pregnant, stop taking 
CADUET and call your doctor right away. 
</li>
<li>Are breastfeeding. CADUET can pass into your breast milk and may harm your 
baby. Do not breastfeed if you take CADUET. 
</li>
<li>Have liver problems. 
</li>
<li>Are allergic to anything in CADUET. The active ingredients are atorvastatin 
calcium and amlodipine besylate. See the end of this leaflet for a complete list 
of ingredients. </li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking CADUET?</span></p>
<p><span class="Bold">Tell your doctor about all of your health conditions, 
including, if you have:</span></p>
<ul>
<li>heart disease 
</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 
</li>
<li>thyroid problems 
</li>
<li>kidney problems 
</li>
<li>or drink more than 2 glasses of alcohol daily </li>
</ul>
<p>Tell your doctor about all the medicines you take including prescription and 
nonprescription medicines, vitamins and herbal supplements. CADUET and some 
other medicines can interact, causing serious side effects. Especially tell your 
doctor if you take medicines for:</p>
<ul>
<li>your immune system 
</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
</li>
<li>birth control 
</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> 
</li>
<li>HIV (AIDS) </li>
</ul>
<p>You can use nitroglycerin and CADUET together. If you take nitroglycerin for 
<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (angina), do not stop taking it while taking CADUET.</p>
<p>Know all the medicines you take. Keep a list of them with you to show your 
doctor and pharmacist.</p>
<p><span class="Bold">How should I take CADUET?</span></p>
<ul>
<li>Take CADUET once a day, exactly as your doctor tells you. Do not change your 
dose or stop CADUET without talking to your doctor. 
</li>
<li>Take CADUET each day at any time of day, at about the same time each day. 
CADUET can be taken with or without food. 
</li>
<li>Do not break the tablets before taking them. Talk to your doctor if you have 
a problem swallowing pills. 
</li>
<li>Your doctor should start you on a low-fat diet before giving you CADUET. 
Stay on this low-fat diet when you take CADUET. 
</li>
<li>CADUET comes in many different strengths. Your doctor will test your 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and blood pressure to find the right dose for you. 
</li>
<li>If you miss a dose, take it as soon as you remember. Do not take CADUET if 
it has been more than 12 hours since your missed dose. Just take the next dose 
at your regular time. Do not take 2 doses of CADUET at the same time. 
</li>
<li>If too much CADUET is taken by <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, call your doctor or poison control 
center, or go to the nearest emergency room. </li>
</ul>
<p><span class="Bold">What should I avoid while taking CADUET?</span></p>
<ul>
<li>Avoid getting pregnant. If you get pregnant, stop taking CADUET right away 
and call your doctor. 
</li>
<li>Do not breastfeed. CADUET can pass into your breast milk and may harm your 
baby. </li>
</ul>
<p><span class="Bold">What are possible side effects of CADUET?</span></p>
<p><span class="Bold">CADUET can cause serious side effects. These side effects 
happen only to a small number of people. Your doctor can monitor you for them. 
These side effects usually go away if your dose is lowered or CADUET is stopped. 
These serious side effects include:</span></p>
<ul>
<li>
<span class="Bold">Muscle problems.</span> CADUET can cause serious muscle 
problems that can lead to kidney problems, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. You have a 
higher chance for muscle problems if you are taking certain other medicines with 
CADUET. 
</li>
<li>
<span class="Bold">Liver problems.</span> CADUET can cause liver problems. 
Your doctor may do blood tests to check your liver before you start taking 
CADUET and while you take it. </li>
</ul>
<p><span class="Bold">Call your doctor right away if:</span></p>
<ul>
<li>you have muscle problems like <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that happen 
without a good reason, especially if you also have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or feel more tired 
than usual 
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or 
throat that may cause difficulty in breathing or swallowing which may require 
treatment right away. 
</li>
<li>you have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> 
</li>
<li>you are passing brown or dark-colored urine 
</li>
<li>you feel more tired than usual 
</li>
<li>your skin and white of your eyes get yellow 
</li>
<li><span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span>. </li>
</ul>
<ul><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> that does not go away or gets worse.</span> 
Sometimes, when you start CADUET or increase your dose, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> can get worse 
or a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> can happen. If this happens, call your doctor or go to the 
emergency room right away. </li></ul>
<p>Common side effects of CADUET include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your legs or ankles (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) 
</li>
<li>hot or warm feeling in your face (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>) 
</li>
<li>irregular heartbeat (<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>) 
</li>
<li>very fast heartbeat (heart <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>) 
</li>
<li>muscle and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> 
</li>
<li>alterations in some laboratory blood tests 
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 
</li>
<li>extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </li>
</ul>
<p>Additional side effects have been reported: tendon problems.</p>
<p>Talk to your doctor or pharmacist about side effects that bother you or do 
not go away.</p>
<p>There are other side effects of CADUET. Ask your doctor or pharmacist for a 
complete list.</p>
<p><span class="Bold">How do I store CADUET?</span></p>
<ul>
<li><span class="Bold">Store CADUET at room temperature, 68 to 77°F (20 to 
25°C).</span></li>
<li><span class="Bold">Do not keep medicine that is out-of-date or that you no 
longer need.</span></li>
<li>Keep CADUET and all medicines out of the reach of children. <span class="Bold">Keep medicines in places where children cannot get it.</span>
</li>
</ul>
<p><span class="Bold">General information about CADUET</span></p>
<p><span class="Bold">Medicines are sometimes prescribed for conditions that are 
not mentioned in patient information leaflets. Do not use CADUET for a condition 
for which it was not prescribed. Do not give CADUET to other people, even if 
they have the same problem you have. It may harm them.</span></p>
<p><span class="Bold">This leaflet summarizes the most important information about 
CADUET. If you want more information, talk with your doctor. Ask your doctor or 
pharmacist for information about CADUET written for health professionals. You 
can also go to the CADUET website at <span class="Underline">www.CADUET.com</span>, or call 866-514-0900.</span></p>
<p><span>What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?</span></p>
<p>You have high blood pressure when the force of blood against the walls of 
your arteries stays high. This can damage your heart and other parts of your 
body. Drugs that lower blood pressure lower your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</p>
<p><span>What is angina (<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>)?</span></p>
<p>Angina is a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that keeps coming back when part of your heart does not get 
enough blood. It feels like something is pressing or squeezing your chest under 
the breastbone. Sometimes you can feel it in your shoulders, arms, neck, jaw, or 
back.</p>
<p><span>What is <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>?</span></p>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> is a fat-like substance made in your body. It is also found in 
foods. You need some <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> for good health, but too much is not good for 
you. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> can clog your blood vessels.</p>
<p><span>What is a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>?</span></p>
<p>A <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> occurs when heart muscle does not get enough blood. Symptoms 
include <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, trouble breathing, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Heart muscle cells 
may be damaged or die. The heart cannot pump well or may stop beating.</p>
<p><span>What is a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>?</span></p>
<p>A <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occurs when nerve cells in the brain do not get enough blood. The 
cells may be damaged or die. The damaged cells may cause <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or problems 
speaking or thinking.</p>
<p>WHAT ARE THE INGREDIENTS IN CADUET?</p>
<p><span class="Bold">Active ingredients:</span> amlodipine besylate, atorvastatin 
calcium</p>
<p><span class="Bold">Inactive ingredients:</span> calcium carbonate, 
croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, 
polysorbate 80, hydroxypropyl cellulose, purified water, colloidal silicon 
dioxide (anhydrous), magnesium stearate </p>
<p><span class="Bold">Film coating:</span> Opadry® II White 85F28751 (polyvinyl 
alcohol, titanium dioxide, PEG 3000 and talc) or Opadry® II Blue 85F10919 
(polyvinyl alcohol, titanium dioxide, PEG 3000, talc, and FD&amp;C blue #2)</p>
<p><span class="Bold">Rx only</span></p>
<p>Manufactured by Pfizer Ireland Pharmaceuticals<br>Dublin, Ireland</p>
<div class="Figure"><img alt="image of Pfizer logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=Pfizer%20logo.jpg"></div>
<p>LAB-0347-3.0<br>July 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">2.5 mg/20 mg*</span></p>
<div class="Figure"><img alt="image of 2.5/20 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2001.jpg"></div>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">2.5 mg/40 mg*</span></p>
<p><img alt="image of 2.5/40 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2002.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">5 mg/10 mg*</span></p>
<p><img alt="image of 5/10 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2003.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">5 mg/20 mg*</span></p>
<p><img alt="image of 5/20 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2004.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">5 mg/40 mg*</span></p>
<p><img alt="image of 5/40 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2005.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">5 mg/80 mg*</span></p>
<p><img alt="image of 5/80 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2006.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">10 mg/10 mg*</span></p>
<p><img alt="image of 10/10 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2007.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">10 mg/20 mg*</span></p>
<p><img alt="image of 10/20 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2008.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">10 mg/40 mg*</span></p>
<p><img alt="image of 10/40 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2009.jpg"><br><span class="Bold"></span></p>
<p><span class="Bold">Caduet <span class="Sup">®</span></span><br>(amlodipine 
besylate /<br>atorvastatin calcium)</p>
<p><span class="Bold">10 mg/80 mg*</span></p>
<p><img alt="image of 10/80 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb&amp;name=package%20label%2010.jpg"></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5672(NDC:0069-2970)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;252</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5672-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">09/21/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5699(NDC:0069-2980)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;254</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5699-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">11/02/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3287(NDC:0069-2150)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;051</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3287-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3287-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">04/15/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-1207(NDC:0069-2170)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;052</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-1207-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-1207-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">01/12/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5179(NDC:0069-2190)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;054</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5179-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">11/11/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5420(NDC:0069-2260)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;058</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5420-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">09/14/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5567(NDC:0069-2160)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;101</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5567-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">11/30/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5209(NDC:0069-2180)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;102</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5209-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5209-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">01/18/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5200(NDC:0069-2250)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;104</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5200-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5200-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">12/27/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CADUET 		
					</strong><br><span class="contentTableReg">amlodipine besylate and atorvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5523(NDC:0069-2270)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE BESYLATE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ATORVASTATIN CALCIUM</strong> (ATORVASTATIN) </td>
<td class="formItem">ATORVASTATIN CALCIUM</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;CDT;108</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5523-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5523-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021540</td>
<td class="formItem">04/15/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>af139a54-d863-4c91-9c29-fc6dec361a0c</div>
<div>Set id: 909fad96-a941-443a-a39f-4f93607410fb</div>
<div>Version: 1</div>
<div>Effective Time: 20091130</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
